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  1 
A. MAIN INTRODUCTION 
 
1. The Pancreas 
The pancreas is an endoderm derived glandular organ that is located in the 
abdominal cavity. It is made up of two different tissue types called exocrine and 
endocrine pancreas, both of which have different functions in the body. The exocrine part 
of the pancreas comprises the majority of the pancreatic mass (~90%) while endocrine 
part makes up only a small proportion of it (~2%) (Githens 1988). Three different cell 
types, termed acinar, centroacinar and pancreatic ductal cells, form the exocrine pancreas 
(Figure 1A). Acinar cells, the major cell population in the exocrine pancreas, secrete 
digestive enzymes (i.e proteases, amylase, lipase and nucleases) many of which are not 
active until they reach the digestive tract (Slack 1995) thereby protecting the pancreas 
from hydrolytic damage. Pancreatic ducts both transport these acinar cell digestive 
enzymes into the digestive tract and secrete bicarbonate ions which regulate the pH level 
in the duodenum. Centroacinar cells, which comprise the minor cell population in the 
exocrine pancreas, connect the acini (cluster of acinar cells) with pancreatic ducts. The 
endocrine part of the pancreas, on the other hand, is composed of five different cell types 
each of which can secrete different hormones directly into the blood stream (Figure 1B). 
These endocrine cells are insulin producing beta (β) cells, glucagon producing alpha (α) 
cells, somatostatin producing delta (δ) cells, pancreatic polypeptide producing (Pp) cells 
and ghrelin producing epsilon (ε) cells. Endocrine cell hormones are mainly involved in 
carbohydrate metabolism (Rovasio 2010). Insulin (hypoglycemic hormone), for instance, 
stimulates the muscle and adipose tissue cells to take up the glucose from the blood 
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stream. Glucagon (hyperglycemic hormone), on the other hand, has an opposite effect to 
that of insulin. It causes the conversion of glycogen stored in the liver into glucose which 
is then released into the blood stream. Somatostatin is synthesized and secreted by delta 
cells in pancreas, neuroendocrine cells in the central nervous system and cells in the 
gastrointestinal system (Reichlin 1983; Reichlin 1983). Consistent with its secretion from 
different cell types, somatostatin has a broad effect throughout the body mainly as an 
inhibitor of endocrine systems (Hauge-Evans, King et al. 2009) such as suppression of 
growth hormone secretion from the anterior pituitary (Spencer, Berry et al. 1991) and 
suppression of gastrointestinal peptide hormone release (Low 2004). In the pancreas 
somatostatin ensures the inhibition of insulin and glucagon release via a paracrine 
secretion (Rovasio 2010). Pancreatic polypeptide provides an inhibitory feedback 
mechanism for exocrine pancreatic secretion after meals (Lonovics, Devitt et al. 1981). 
Ghrelin hormone is mainly produced by stomach cells and epsilon cells in pancreas to a 
lesser extent. Beside its other roles such as stimulation of appetite, effects of ghrelin on 
beta cell development, function and survival have also been reviewed (Granata, Baragli et 
al. 2010). 
The endocrine cells are organized as cell clusters which are called islets of 
Langerhans (Langerhans 1868) and these islets locate in close proximity to capillaries. 
Although the cytoarchitecture of islets depends on the animal species, they are scattered 
throughout the exocrine pancreas in the mammals (Gregoire and Bendayan 1986) more 
located in the tail than in the body and head of the human pancreas (Rovasio 2010). In 
rodents, beta cells tend to locate at the core of the islets and be surrounded by the other 
endocrine cell types. In humans, however, beta cells are distributed heterogeneously 
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throughout the islet. The number of beta cells in human islets is also proportionately less 
than those found in rodents (Cabrera, Berman et al. 2006). In a rodent islet, beta cells 
(~65-80%) are the main cell population, followed by alpha cells (~15-20%), delta cells 
(3-10%), Pp cells (3-5%) and epsilon cells (1%), respectively. 
 
2. Pancreas Development 
In mammals, after fertilization, the fertilized egg (ovum) undergoes a series of 
cell divisions with the result that a mass of cells is formed within the zona striata. The 
resulting structure is called a morula and the cells forming the morula are termed 
blastomeres. The cells of the morula are then arranged into an outer cell layer 
(trophectoderm) and an inner cell mass (ICM). This structure is called a blastocyst in 
which trophectoderm cells will develop to placenta and ICM will develop to embryo 
proper. The next developmental stage is termed gastrulation in which through the 
movement of cells, three embryonic layers (endoderm, ectoderm and mesoderm) are 
formed resulting in a structure called gastrula (Gray and Williams 1989). Before 
organogenesis, digestive track endoderm is regionalized into organ specific domains via 
anterior-posterior and dorsal-ventral patterning events which are driven by the inductive 
signals from adjacent mesodermal structures. During organogenesis, the pancreas 
develops as two separate protrusions from foregut endoderm that are surrounded by 
mesenchyme. These early pancreatic protrusions are called pancreatic ventral and dorsal 
buds, both of which fuse together to give rise to an intact pancreas (Figure 2). Formation 
of the pancreas starts with the condensation of mesenchyme that is lying on top of  the 
dorsal foregut endoderm (Gittes 2009). This mesenchymal condensation is followed by 
  4 
evagination of forget endoderm into the mesenchyme giving rise to the pancreatic dorsal 
bud (mouse 9.5 days post coitum (dpc)) (Gittes 2009). Inductive signals from the 
notochord, dorsal aorta and surrounding mesoderm are necessary for pancreatic dorsal 
bud formation (Neoptolemos 2010). Through these signals, activin-βB and fibroblast 
growth factor 2 (FGF2) from the notochord suppress endodermal Sonic hedgehog (Shh) 
expression thereby allowing pancreatic dorsal bud formation (Hebrok, Kim et al. 1998). 
Otherwise hedgehog signaling prevents pancreas development by repressing early 
expression of Pancreatic and duodenal homeobox 1 (Pdx1) gene (Apelqvist, Ahlgren et 
al. 1997). Signals from endothelium of the dorsal aorta were also shown to be important 
for pancreatic dorsal bud development (Lammert, Cleaver et al. 2001). After the 
formation of dorsal bud, the pancreatic ventral bud arises by evagination of foregut 
endoderm underneath of hepatic bud (Gittes 2009). Following the bud formation these 
dorsal and ventral pancreatic buds keep forming new protrusions (mouse 10.5-11.5 dpc) 
resulting in highly branched structures under the control of proliferative signals from 
pancreatic mesenchyme (Slack 1995). The formation of dorsal and ventral pancreatic 
buds is morphologically similar but the signals which are controlling the bud formation 
are different. The absence of notochord, for instance, does not affect the ventral pancreas 
formation (Kim, Hebrok et al. 1997). Instead, lateral plate mesoderm (LPM) is necessary 
for pancreatic ventral bud formation (Kumar, Jordan et al. 2003). Signals from LPM are 
not identified yet but activin, bone morphogenetic protein 4 (BMP4) or retinoic acid (RA) 
are considered possible candidates (Kumar, Jordan et al. 2003). The pancreatic ventral 
bud arises from a region under the liver competent region (mouse 10 dpc). FGF signaling 
from cardiac mesoderm favors hepatic bud formation over pancreatic ventral bud 
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formation (Jung, Zheng et al. 1999). The septum transversum was also shown to have an 
effect in favor of liver formation over ventral pancreas formation via BMP signaling 
(Rossi, Dunn et al. 2001). On the other hand, a proper balance of BMP is necessary for 
pancreatic ventral bud formation since its complete absence was shown to prevent ventral 
bud formation (Kumar, Jordan et al. 2003). The next step is the coiling movement of the 
digestive track endoderm (mouse 11.5 dpc) which brings two pancreatic buds in close 
proximity to fuse and form an intact pancreas (mouse 12.5 dpc) (Pan and Wright 2011). 
Pancreas development in rodents is divided into two stages. The first stage is 
called the primary transition (mouse 9.5-12.5 dpc, not seen in human) in which the first 
differentiated endocrine cells appear in the pancreatic dorsal bud. In this stage, pancreatic 
progenitor cells proliferate and form the multilayered epithelium. These cells are called 
primary pancreatic multi-potent progenitor cells (1◦ MPC) which can give rise to all 
pancreatic cell lineages. During the primary transition glucagon-producing alpha cells are 
the only endocrine cell line that originates from 1◦ MPCs. Initially all these endocrine 
cells are glucagon positive, then some of them become both glucagon and insulin positive 
and finally some of them turn into insulin positive only. Still a majority of them are only 
positive for glucagon (Cleaver and MacDonald 2010). These early endocrine cells are 
different from their mature counterparts and the functional importance of these cells is 
still unknown. Many microlumen structures are also formed during the primary 
transition. After the primary transition and fusion of buds, the pancreatic epithelium 
keeps expanding and is remodeled into a more complex plexus structure. Meanwhile the 
pancreatic epithelium is segregated into `tip` and `trunk` domains in which tip domains 
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include secondary pancreatic multipotent progenitor cells (2◦ MPC) and trunk domains 
include endocrine/duct bipotential progenitor cells. 
The second stage is called the secondary transition (mouse 13.5-16.5 dpc) in 
which a massive wave of endocrine cell formation is seen. The endocrine cells formed at 
this stage are distinct from those formed in the primary transition (Cleaver and 
MacDonald 2010). In this stage formation of three main pancreatic lineages occurs: 
acinar cells, ductal cells and endocrine cells. Levels of insulin hormone and acinar 
enzymes are exponentially increased at this stage (Pictet R 1972). Acinar cells are 
differentiated from 2◦ MPCs at the tip domains (mouse 14.5 dpc) during the secondary 
transition and keep proliferating to increase the acinar cell mass after the secondary 
transition. During the secondary transition endocrine cells also differentiate from bipotent 
progenitor cells left behind in the trunk region as the tip region continues to grow (Zhou, 
Law et al. 2007). These endocrine cell precursors leave the trunk and aggregate into 
endocrine cell clusters, which are called islets of Langerhans, by birth (Piper, Brickwood 
et al. 2004). The exact mechanism of this cell escape from the trunk epithelium is not 
well understood and two different cellular processes have been proposed: a) epithelial-to-
mesenchymal transition (EMT); and b) orthogonal cell division. In the EMT model, the 
mesenchymal state of escaped cells should be transient since they have to return back to 
an epithelial state before endocrine differentiation. The only support for this model is 
expression of Snail homolog 2 (Snail2) in escaped cells after Neurogenin 3 (Ngn3) 
expression (Rukstalis and Habener 2007). Snail2 is a close paralog of Snail1 which is the 
master regulator for EMT, working by repressing E-cadherin expression as well as other 
epithelial characteristics (del Barrio and Nieto 2002; Katoh and Katoh 2006). On the 
  7 
other hand, according to the orthogonal cell division model, endocrine progenitor cells 
can change their cell division axis and start to divide parallel to the epithelial lumen 
(Pictet R 1972). In this model, asymmetric cell division retains one progenitor daughter 
cell in the epithelium (which may keep forming new endocrine progenitors or 
differentiate into ductal cells) and releases the other one out the epithelial tube. After 
birth, differentiated endocrine and exocrine cells start to proliferate, maintaining tissue 
growth in parallel with other embryonic organs. Postnatal replication of beta cells slows 
and stops until weaning. A distinguishable mature islet structure, in which a beta cell core 
is surrounded by other endocrine cells, is seen during the first few weeks after birth. 
Development of the early pancreas is summarized in Figure 3.  
 
3. Gene Expression Patterns during Pancreas Development and Lineage Allocation 
In mice at 8.5 dpc uncommitted prepancreatic foregut endoderm expresses Pdx1, 
Motor neuron and pancreas homeobox (Mnx1) (also known as Hlxb9), Hepatocyte 
nuclear factor 1 beta (Hnf1b) and Forkhead box A2 (FoxA2) (also known as Hnf3b), 
GATA binding protein 4 (Gata4), and GATA binding protein 6 (Gata6). Mnx1 is one of 
the earliest genes expressed during pancreas development and later then in the mature 
beta cells. Its expression is essential for pancreatic dorsal bud formation (Li, Arber et al. 
1999). Unlike the dorsal bud, pancreatic ventral bud can develop in the absence of MNX1 
but produces less beta cells than usual with an immature beta cell phenotype. Pdx1 is 
another gene that is expressed during early pancreatic development and then in the 
mature beta cells. In the absence of PDX1, pancreas agenesis occurs (Jonsson, Carlsson 
et al. 1994) even though pancreatic buds form initially (mouse 9.5 dpc) without further 
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growth and branching. Neither a secondary transition nor acinar/endocrine cell formation 
is observed in the absence of PDX1 (Offield, Jetton et al. 1996). Gata4 is another gene 
that is expressed throughout the early pancreatic epithelium and it was shown to control 
Mnx1 and Pdx1 expression in the pancreatic ventral bud (Watt, Zhao et al. 2007). In the 
absence of GATA4, ventral bud does not form but the dorsal bud does. After the 
secondary transition Gata4 is expressed only in 2◦ MPCs at the tip of branching 
epithelium and then it is confined to acinar cells in the mature pancreas (Ketola, 
Otonkoski et al. 2004; Decker, Goldman et al. 2006). FOXA2 and HNF1B also control 
Pdx1 expression by binding its promoter region during early pancreas development 
(Gerrish, Cissell et al. 2001). In the absence of HNF1B it was shown that the ventral 
pancreatic bud does not form without effecting formation of the pancreatic dorsal bud. 
However the progenitor cell population in that dorsal bud does not expand (Haumaitre, 
Barbacci et al. 2005). During the secondary transition Hnf1b is expressed in 
endocrine/duct bipotent progenitor cells located in the trunk epithelium and only in ductal 
cells in the adult pancreas (Solar, Cardalda et al. 2009). Pancreas transcription factor 1a 
(Ptf1a), which encodes a bHLH transcription factor, is expressed during early pancreas 
development (mouse 9.5 dpc) and then in the mature acinar cells only. Like PDX1, 
PTF1A is indispensable for pancreas organogenesis. PTF1A was also shown to be 
necessary for pancreatic ventral bud formation as well as proper development of 
pancreatic dorsal bud (Masui, Long et al. 2007). Beside its early role in pancreas 
development, Ptf1a expression is required for acinar cell differentiation (Krapp, Knöfler 
et al. 1998). In the absence of PTF1A, the exocrine pancreas fails to develop and the 
number of islet cells is reduced in mice (Krapp, Knöfler et al. 1998). Between 9.5-12 dpc 
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in mouse, Ptf1a and Pdx1 are coexpressed in 1◦ MPCs (Kawaguchi, Cooper et al. 2002). 
Moreover, 1◦ MPCs also express Mnx1, SRY-gene containing box 9 (Sox9), Hnf1b, 
FoxA2, Hepatocyte nuclear factor 6 (Hnf6), NK6 homeobox 1 (Nkx6.1), Gata4 and Gata6 
(Pan and Wright 2011). 
During the secondary transition, 2◦ MPCs at the tip epithelium express Pdx1, 
Ptf1a, Carboxypeptidase A1 (Cpa1), Sox9, Nkx6.1, Hnf1b, Gata4 and Nuclear receptor 
subfamily 5 group A member 2 (Nr5a2). These cells have potential to give rise to all adult 
pancreatic lineages: acinar, ductal and endocrine cells. On the other hand, duct/endocrine 
bipotential progenitor cells at the trunk epithelium express Pdx1, Sox9, Nkx6.1, Hnf1b, 
Hnf6, FoxA2 and Gata4. Endocrine progenitor cells arise from this duct/endocrine 
bipotent progenitor cell population by expressing intense amounts of Ngn3 transiently 
(Schwitzgebel, Scheel et al. 2000; Gu, Dubauskaite et al. 2002; Jensen 2004). Beside 
activating other transcription factors (such as Myelin transcription factor 1 (MYT1), 
Islet1 (ISL1) and SNAIL2) which are necessary for endocrine progenitor cell formation, 
the primary role of NGN3 is activation of Neurogenic differentiation 1 (Neurod1) by 
binding its promoter region (Huang, Liu et al. 2000). After Ngn3 expression is turned off, 
NEUROD1 leads the endocrine differentiation program (Cleaver and MacDonald 2010). 
High levels of Ngn3 expression differentiate these cells into endocrine precursor cells, 
which express Mnx1, Myt1, Is1, Neurod1, Insulinoma associated 1  (Insm1), Regulatory 
factor X 6 (Rfx6), Paired box gene 6 (Pax6), Nkx6.1, NK2 homeobox 2 (Nkx2.2), and 
Snail2. Endocrine precursor cells leave the trunk epithelium to form islets of Langerhans 
by assembling into endocrine cell clusters. By the time these cells leave the trunk 
epithelium, Ngn3 expression is turned off (Smith, Gasa et al. 2003). Acinar cells, 
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however, differentiate from 2◦ MPCs at the tip epithelium at around 13.5 dpc in mice. 
These acinar cells express Ptf1a, Gata4, Basic helix-loop-helix family member a15 
(Bhlha15, also known as Mist1), Nr5a2, Prospero-related homeobox 1 (Prox1) and keep 
proliferating after the secondary transition to increase the number of acinar cells. 
Meanwhile, duct/endocrine progenitor cell population also gives rise to ductal cells which 
express Hnf6, Hnf1b, Sox9, Hes1 (Hairy and enhancer of split 1) and FoxA2.  
 
4. Gene Expression Patterns during Endocrine Cell Development 
Endocrine cell development is initiated by Ngn3 expression and in the absence of 
NGN3 mice can not develop endocrine cells (Gradwohl, Dierich et al. 2000). Pan and 
Wright classified the transcription factors directing the endocrine cell fate into three main 
groups: a) general endocrine precursor differentiation factors; b) lineage allocation 
factors; and c) maturation factors (Pan and Wright 2011). Neurod1, Insm1, Rfx6, Isl1, all 
of which are direct targets for NGN3, and NKX6 family factors (Nkx6.1 and Nkx6.2), 
which are not direct targets of NGN3, are considered general endocrine precursor 
differentiation factors. The main function of this class of transcription factors is 
facilitating the formation of the proper number of endocrine cells. The transcription 
factors which are on in endocrine precursor cells are MNX1, MYT1, ISL1, NEUROD1, 
INSM1, RFX6, PAX6, NKX6.1, NKX6.2 and SNAIL2. Lineage allocation class 
transcription factors control the formation of each adult endocrine cell from endocrine 
precursor cells.  PDX1, NKX2.2, Aristaless related homeobox (ARX) and Paired box 
gene 4 (PAX4) are classified into this class of transcription factors. For instance, absence 
of NKX2.2 leads to increased numbers of epsilon cells and a decrease in the number of 
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other endocrine cells without affecting the total number of endocrine cells in mice 
(Sussel, Kalamaras et al. 1998). Absence of PAX4 also reduces the number of beta and 
delta cells while increasing the number of alpha and epsilon cells in mice (Prado, Pugh-
Bernard et al. 2004). Moreover, ARX and PAX4 work antagonistically. Arx expressing 
cells can differentiate into alpha and Pp-cells (Collombat, Mansouri et al. 2003) while 
PAX4 has an opposite effect. Beside its pivotal role in early pancreas development, 
PDX1 is also essential for formation, proliferation and survival of adult beta and delta 
cells. During the secondary transition, deletion of an enhancer that is specifically required 
for Pdx1 expression decreased the formation of beta cells but increased the number of 
other endocrine cells (Fujitani, Fujitani et al. 2006). After the decision of endocrine cell 
fate, maturation factors help the cells to go through terminal differentiation. MAFA, 
FOXA1, FOXA2 and NEUROD1, for instance, are considered maturation factors for beta 
cells.  
 
5. Glucose Metabolism and Role of the Endocrine Pancreas 
Glucose is an important source of energy for cells of the body. Even though most 
of the organs use free fatty acids as primary energy sources, glucose is used as the 
primary fuel in the brain (Siesjö 1988). Since the brain can not synthesize and/or store 
glucose, it requires a well regulated supply of glucose from the blood (Shrayyef and 
Gerich 2010). Most of the glucose in the blood circulation is used by brain, skeletal 
muscle, kidney, blood cells, splanchnic organs and adipose tissue, respectively (Gerich 
1993). Even though there are some other players, the full glucose metabolism in large 
part is regulated by two endocrine hormones: insulin from beta cells and glucagon from 
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alpha cells. These hormones have converse effects during glucose metabolism. Release of 
insulin from beta cells depends mainly on the glucose level and to a lesser extent on 
mannose and fructose levels in the blood. Poorly metabolized sugars (galactose, xylose), 
however, do not stimulate insulin release (Grodsky, Batts et al. 1963). Free fatty acids 
and amino acids were also shown to have an influence on insulin secretion (Brass, 
Abelev et al. 2010). Glucose is transported into beta cells through a glucose transporter 
protein, SLC2A2 (also known as GLUT2) which locates at the beta cell membrane. 
Beside beta cells, SLC2A2 is also found in intestine, liver and kidney cell membranes 
(Bouché, Serdy et al. 2004). Glucose is then metabolized in the beta cells to produce the 
essential signals which are mandatory for exocytosis of insulin containing granules 
(Newgard and McGarry 1995). Briefly, after glucose is metabolized ATP is increased in 
the beta cells, and this results in the closure of ATP-dependent potassium channels on the 
cell membrane. Membrane is depolarized which causes the opening of calcium channels. 
The increased cytoplasmic calcium concentration activates protein kinases and interacts 
with the cell’s secretory machinery which stimulates the exocytosis of insulin secretory 
vesicles. 
Insulin has various roles in cell growth and differentiation as a signaling molecule 
but its major function is involved in glucose metabolism. When the glucose level 
increases in blood circulation after meals, insulin is pumped into the blood stream from 
beta cells. Once insulin reaches target cells in liver, kidney, muscle, and adipose tissue, it 
binds to its tyrosine kinase type receptor on the target cell surface which triggers a 
complex signaling pathway within the target cells. This signaling pathway involves a 
cascade of protein kinases and regulatory proteins. Insulin-receptor interaction has two 
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main consequences: a) glucose release into the plasma from liver and kidney is 
suppressed (Meyer, Dostou et al. 1998); and b) the glucose transporter protein SLC2A4 
(also known as GLUT4), which normally locates intracellular via SLC2A4-containing 
vesicles, in muscle and adipose tissue cells is translocated to the cell membrane to 
increase the glucose uptake by these cells (Oster-Jorgensen, Pedersen et al. 1990; Chang, 
Chiang et al. 2004). Unlike in adipose tissue and muscle cells, insulin does not trigger the 
uptake of glucose in the liver and kidney (Saltiel and Kahn 2001). Instead, i) it promotes 
glycogenesis (glycogen synthesis from glucose) by stimulating glycogen synthase; ii) 
inhibits glycogenolysis (conversion of glycogen to glucose) by inhibiting glucose-6-
phosphatase and phosphorylase both of which are glycogenolysis enzymes; and iii) 
inhibits gluconeogenesis (generation of glucose from non-carbohydrate carbon 
substrates) in the liver (Saltiel and Kahn 2001). Glucagon, on the other hand, increases 
the glucose level in the blood through glycogenolysis (Lecavalier, Bolli et al. 1989). It 
binds to its receptors on hepatocytes. Glucagon-receptor interaction increases 
intracellular cAMP which afterwards enhances glycogenolysis through phosphorylase 
stimulation (Magnusson, Rothman et al. 1995).  
 
6. Diabetes Mellitus 
Diabetes mellitus is a metabolic disease which is characterized by hyperglycemia, 
and complications (i.e. cardiovascular diseases, retinopathy, neuropathy, nephropathy and 
peripheral circulatory diseases) can be lethal unless treated (Bluestone, Herold et al. 
2010). Diabetes was reported to be the sixth leading cause of death in the United States as 
of 2004 (Kung, Hoyert et al. 2008). It can result from defects during insulin secretion 
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and/or insulin action. There are two main types of diabetes which are called type 1 
diabetes (insulin dependent diabetes) and type 2 diabetes (non-insulin dependent 
diabetes). In addition to type 1 and 2, there are also gestational diabetes, which is seen in 
pregnant women due to insufficient amount of insulin hormone, and MODY (Maturity 
onset diabetes of youth) type diabetes in which a single gene related to beta cell 
development or insulin action (i.e. Hepatocyte nuclear factor 1 alpha (Hnf1α), Hnf1b, 
Hepatocyte nuclear factor 4 alpha (Hnf4α), Glucokinase (Gck), Neurod1, Pdx1) is 
mutated. Type 1 diabetes, which accounts for 5-10% of all diagnosed cases of diabetes, 
results from almost complete loss of beta cells due to an autoimmune attack by T cells 
(Roep 2003). Loss of massive numbers of beta cells results in insulin shortage which 
must be compensated with external insulin hormone to control glucose homeostasis. Loss 
of the beta cells after the onset of disease is generally rapid and complete in younger 
children and patients already become dependent on exogenous insulin at the time of 
diagnosis. In older children and adults, however, some beta cells may survive after the 
onset of disease (Roep 2003). Even though the precise mechanism which triggers the 
autoimmune response in type 1 diabetes remains unclear, multiple genes and 
environmental factors (i.e. geographic location, seasonality, diet, viral exposure, 
chemicals, stress etc.) are known to be related to onset of the disease (Ali 2010). Family 
and twin studies have shown that there is a large genetic susceptibility for type 1 diabetes. 
However, a high percentage of recently diagnosed type 1 diabetic patients has no family 
history (Ali 2010). Although occurrence of type 1 diabetes due to a single gene mutation 
is rare, there are two different single gene defects causing type 1 diabetes. These are 
called IPEX syndrome, in which Forkhead box P3 (Foxp3) gene is mutated, and APS-I 
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syndrome, in which the Autoimmune regulator (Aire) gene is mutated. Mutation of these 
genes causes loss of a majority of T lymphocytes which afterwards results in 
overwhelmed autoimmunity and development of diabetes. Instead of single gene 
mutations, genetic variations in several gene loci such as HLA, IDDM2, PTPN22, CD25 
etc., were shown to influence type 1 diabetes (Ali 2010). Of these loci, major 
histocompatibility complex (referred as human leukocyte antigen in human) has the 
greatest contribution in type 1 diabetes occurrence. In type 2 diabetes, which accounts for 
90-95% of all diagnosed cases of diabetes, the beta cells are not destroyed by T cells and 
keep providing insulin. However, the peripheral tissues (i.e. liver, muscle and adipose 
tissue) do not respond to insulin which is called insulin resistance. Existing beta cells try 
to overcome the insulin resistance by overproducing insulin. However, after a point 
glucose homeostasis is still impaired since beta cells are lost gradually by apoptosis. Up 
to 50% of total beta cell mass may be reduced in type 2 diabetes patients over time (Porte 
and Kahn 2001). Insulin resistance-triggered type 2 diabetes can occur due to defects at 
any point of insulin-receptor interaction, glucose uptake pathway and glucose 
phosphorylation after uptake into the target cells. In type 2 diabetic patients as well as 
obese people, the number of insulin receptors on the target cell membranes is reduced. 
However, even a low number of insulin receptors is enough for a moderate response to 
insulin. Based on this fact a reduced insulin response in patients should theoretically be 
due to post-binding defects (Fonseca and John-Kalarickal 2010). The main cause of type 
2 diabetes is not certain yet. However, studies showed that it is linked with genetic 
factors and environmental factors (i.e. high fat and carbohydrate including diet, less 
physical activity, obesity, environmental toxins). In a study in which mouse insulin 
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receptor gene is disrupted (IR+/-), it was shown that single gene disruption causes only a 
minor phenotypic effect. However, the combination of more than one minor defect like in 
insulin receptor and receptor activated intracellular proteins (IR+/- and IRS-1+/- double 
mutation) can mimic the insulin resistance in type 2 diabetes (Brüning, Winnay et al. 
1997; Kadowaki 2000). 
 
7. Current Treatments of Diabetes 
The primary goal in diabetes therapy is restoring glucose homeostasis. Since the 
absence of insulin hormone in type 1 diabetes is the main reason for failure in glucose 
homeostasis, patients should be supplied with external insulin permanently or a new 
source supplying insulin should be created within the body. The current main therapy for 
type 1 diabetes is called insulin replacement in which patients take external insulin 
subcutaneously by daily shots. Beside multiple daily injections, there are insulin pumps 
that provide continuous insulin infusion for the patients (Lepore, Dodesini et al. 2003). 
External insulin was originally obtained from animal pancreases (i.e. bovine or porcine 
insulin), but its use is now discontinued due to immune reactions. Recombinant human 
insulin is now made in Escherichia coli and/or in Saccharomyces cerevisiae by 
recombinant DNA technology (Heller, Kozlovski et al. 2007). There are even 
commercially available human insulin analogues, the amino acid sequences of which are 
slightly modified to increase the absorbance efficiency of insulin after injection (Cohan 
and Peters 2010). Since the amount of insulin that the body needs depends on glucose 
levels of blood, which change over time, the frequent monitoring something required. 
The necessary amount of insulin in the body should be adjusted based on blood glucose 
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levels otherwise hypo- or hyperglycemia may occur. However, even if the blood glucose 
level is monitored frequently insulin replacement therapy can not completely mimic the 
normal insulin secretion from living beta cells. Another disadvantage is the fact that 
patients are dependent external insulin on for their entire life. Beside, other complications 
such as local allergic skin reactions at the site of insulin injection (Radermecker and 
Scheen 2007), systemic insulin allergy (Harmel, Mathur et al. 2004), loss of 
subcutaneous fat (lipoatrophy) at the site of insulin injection (Radermecker, Piérard et al. 
2007), and accumulation of extra fat (lipohypertrophy) at the site of insulin injection 
(Vardar and Kızılcı 2007) have also been reported as side effects of the current insulin 
replacement therapy. 
Transplantation of a cadaveric whole pancreas with or without kidney to type 1 
patients is an alternative treatment which is first performed in 1966 in the University of 
Minnesota (Kelly, Lillehei et al. 1967) and improved over time. Recent advances in the 
field such as discovery of new immunosuppressive agents, improved matching between 
donor and recipient, and usage of bladder drainage, have positively improved the survival 
rate of grafts and reduced chance of graft rejection (Odorico, Becker et al. 2000). 
However, risks due to surgery and the use of immunosuppressive agents are still present 
which limits the application of this procedure to people who also need a kidney transplant 
and/or who cannot use insulin replacement therapy safely (Cohan and Peters 2010). 
In addition to whole pancreas transplantation, successful infusion of isolated beta 
cells/islets from cadavers into type 1 diabetes patients was first reported in the University 
of Minnesota in 1977 (Najarian, Sutherland et al. 1977) and has been used recently as an 
experimental therapy. Most patients receiving islet transplantation maintained insulin 
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independence beyond 2 years (Farney, Hering et al. 1998) and the longest insulin 
independence was reported for 13 years (Robertson, Lanz et al. 2001). Unlike whole 
pancreas transplantation, advantages of beta cells/islets transplantation are less antigen 
loading, easier surgery and lower morbidity (Lakey, Mirbolooki et al. 2006). However, 
infusion of beta cells/islets into the liver through the portal vein was reported to cause 
some side effects including bleeding, portal vein thrombosis, and portal hypertension 
(Srinivasan, Huang et al. 2007). Like whole pancreas transplantations, cell infusion 
therapy also necessitates the suppression of the immune system lifelong. Moreover a 
shortage of cadaveric pancreas and the necessity for at least two cadaveric donors to 
isolate enough islet cells for one recipient are other obstacles for beta cells/islets 
transplantation treatments (Cohan and Peters 2010).  
 
8. Possible Sources for Beta Cell Replacement 
Problems such as the shortage of pancreas organ donors and necessity of intensive 
immunosuppression in current treatments for diabetes have caused researchers to seek for 
alternative sources of glucose-responsive insulin producing cells. Transplantation of beta 
cells from animals into humans (Xenotransplantation) is one of these possible ways to 
provide an alternative beta cell source. A high level of similarity between human and pig 
insulin protein (only one amino acid is different) (Lakey, Mirbolooki et al. 2006), lower 
sensitivity of porcine islets against autoimmunity than human islets (Koulmanda, Qipo et 
al. 2003) and successful genetic manipulations and breeding of pigs makes them the best 
candidate as beta cell donor for xenotransplantation studies. Transplantation of pig islets 
to non-human primates was performed in which diabetic animals controlled their glucose 
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metabolism more than 100 days after transplantation (Hering, Wijkstrom et al. 2006). 
However, many improvements are necessary for xenotransplantation studies before 
human clinical trials can take place, and immunosuppression is still essential for this type 
of treatment to prevent rejection of donor cells. 
Another possible source for beta cell production is embryonic stem (ES) cells 
and/or induced pluripotent stem (IPS) cells. Soria et al. were first to show the potential of 
mouse ES cells to become insulin-positive cells which could rescue streptozotocin treated 
diabetic mice (Soria, Roche et al. 2000). There after, many other groups reported 
generation of insulin producing beta-like cells from mouse and human ES cells by using 
slightly different differentiation protocols. In these protocols, in vivo developmental 
principles of mouse pancreas were applied to in vitro systems (D'Amour, Bang et al. 
2006; Kroon, Martinson et al. 2008; Zhang, Jiang et al. 2009). However, these 
differentiation protocols resulted in either a low number of insulin positive cells, teratoma 
formation, an immature beta cell phenotype (no c-peptide production and/or no glucose 
response), or improper endocrine cell specification (double positiveness for endocrine 
hormones) (Naujok, Burns et al. 2011). 
Generation of beta cells by reprogramming of terminally differentiated other adult 
cells may be another possible new beta cell source. In differentiated cell types ectopic 
expression of transcription factors, which play a role in their normal developmental 
growth, and/or administration of extracellular soluble factors, can make reprogramming 
possible. In a pioneering study, for instance, Weintraub et al. activated the muscle cell 
phenotype in a variety of non-muscle tissue culture cells by overexpressing the myogenic 
factor MyoD (Weintraub, Tapscott et al. 1989). Some other examples of cell 
  20 
reprogramming are, formation of hepatocyte-like cells from pancreatic exocrine cells 
(Shen, Slack et al. 2000), macrophages from B lymphocytes (Xie, Ye et al. 2004), 
neurons from fibroblasts (Vierbuchen, Ostermeier et al. 2010) and cardiomyocytes from 
fibroblasts (Ieda, Fu et al. 2010). Beta cell reprogramming from hepatocytes has been 
widely studied recently because of the developmental relatedness of liver and pancreas. 
Activation of pancreatic gene expression in hepatocyte was shown to be possible by 
ectopic expression of pancreatic master gene Pdx1 in the mouse liver (Ferber, Halkin et 
al. 2000). Formation of insulin positive beta-like cells by ectopic expression of Pdx1 in 
cultured human hepatocytes was also shown by Ferber`s group (Sapir, Shternhall et al. 
2005). However, in all liver to pancreas reprogramming studies the number of insulin 
producing cells and amount of insulin produced/secreted by reprogrammed cells are low 
indicating that reprogramming is not yet effective (Meivar-Levy, Aviv et al. 2010). More 
recently, in vivo regeneration of pancreatic mouse endocrine cells from pancreatic 
exocrine cells was shown by overexpressing three important pancreatic transcription 
factor genes, Pdx1, Ngn3 and MafA (Zhou, Brown et al. 2008).
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Figure 1: Pancreatic cells 
(A) Pancreatic exocrine cells. Adapted from “Developmental biology of the pancreas,” 
by J. M. W. Slack, 1995, Development, 121, p. 1569-1580 (B) Pancreatic endocrine cells. 
Adapted from “Pancreatic organogenesis- developmental mechanisms and implications 
for therapy,” by H. Edlund, 2002, Nature Review Genetics, 3, p. 524-532 
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Figure 2: Dorsal and ventral pancreatic buds in developing mouse embryo 
Location of dorsal and ventral pancreatic buds in mouse embryo at 10 and 12 dpc 
respectively. Adapted from “Pancreatic organogenesis- developmental mechanisms and 
implications for therapy,” by H. Edlund, 2002, Nature Review Genetics, 3, p. 524-532 
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Figure 3: Development of pancreas 
Murine pancreas development from 9 dpc to adult. Adapted from “Pancreas 
organogenesis: from bud to plexus to gland,” by F. C. Pan and C. Wright, 2011, 
Developmental Dynamics, 240, p. 530-565
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B. EXPERIMENTAL OBJECTIVES 
 
Diabetes is a life threatening disease the prevalence of which is increasing 
worldwide. According to American Diabetes Association (ADA) and World Health 
Organization (WHO) nearly 19 million people in United States are diagnosed with 
diabetes and more than 346 million people worldwide are diabetic. Despite common 
usage, therapy provided by external insulin shots can not imitate the normal insulin 
secretion pattern as efficiently as beta cells do. The shortage of cadaveric pancreases is 
the major limitation for beta cell/islet transplantation therapy in which immune 
suppression is also necessary. These limitations can potentially be overcome by 
reprogramming of terminally differentiated adult cells into insulin expressing, glucose 
sensitive beta-like cells. Any method providing beta cell neogenesis from a patient`s own 
adult cells by cell reprogramming will eliminate the necessity for immune suppression. 
Production of new beta cells from highly regenerative organs such as liver and/or from 
organs in which alteration of its cells does not affect the original function of the organ 
such as exocrine pancreas will also solve the shortage problem of starting cells. Based on 
this possibility many studies regarding beta cell reprogramming have been performed in 
liver cells both in vivo and in vitro. However, despite some promising results such as 
insulin expression, or amelioration of diabetic animals by newly produced insulin 
positive cells, none of these studies showed a true beta cell neogenesis. Overexpression 
of Pdx1, Ngn3 and MafA in exocrine pancreas of mouse has been shown to produce 
insulin positive beta-like cells which were capable of rescuing streptozotocin-treated 
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NOD-SCID (non-obese diabetic severe combined immunodeficiency) diabetic mice 
(Zhou, Brown et al. 2008), although how beta-like these cells are is still not known. 
In this thesis we used the same transcription factors; Pdx1, Ngn3 and MafA, but 
unlike Zhou et al., we cloned all three genes into a single adenoviral construct which we 
call Ad-PNM.  
The first aim of this thesis was to investigate the reprogramming competency of 
different cell types from different species at different developmental stages into beta-like 
cells through Ad-PNM. 
The second aim was to investigate the effect of Ad-PNM on the AR42J-B13 cell 
line, which gave the highest proportion of insulin positiveness after transduction with Ad-
PNM, to see if the cell transformation we saw after Ad-PNM transduction is really a 
reprogramming event or not.  
The third aim was to further characterize the effects of Ad-PNM on mouse 
hepatocyte-derived small cells, and to explore if small molecules and histone modifying 
agents can increase the effects.  
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Chapter 1 Investigation the Reprogramming Competency to Ad-PNM of Different 
Cell Types from Different Species at Different Developmental Stages 
 
1.1. Introduction 
In multi-cellular organisms during embryonic development, cells decide which 
developmental commitment pathways they will follow under the control of extracellular 
inducing factors, and eventually become one of about 200 different cell types of the 
vertebrate body (Slack 2006). Once a cell terminally differentiates it becomes relatively 
stable and persists long term with or without cell division. Recent studies showed that it 
is also possible to reprogram one differentiated cell type to another by overexpression of 
specific transcription factors which are responsible for the relevant commitment 
processes in normal development (Zhou, Brown et al. 2008). For instance some examples 
of reprogramming event that have been described are: formation of myogenic phenotype 
in a variety of non-muscle tissue culture cells by overexpression of MyoD (Weintraub, 
Tapscott et al. 1989), formation of hepatocytes from pancreatic exocrine cells (Shen, 
Slack et al. 2000), macrophages from B lymphocytes (Xie, Ye et al. 2004), neurons 
(Vierbuchen, Ostermeier et al. 2010) and cardiomyocytes (Ieda, Fu et al. 2010) from 
fibroblasts. In a recent study, generation of pancreatic beta cells from pancreatic exocrine 
cells in immunodeficient mice was shown by overexpression of Pdx1, Ngn3 and MafA 
transcription factors in vivo (Zhou, Brown et al. 2008). Of these examples, formation of 
beta cells is of particular interest from the point of view of the necessity to find an 
alternative beta cell source because of the problems in current diabetes therapies. 
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In this study, we looked at the reprogramming competency of different cell types 
from different species at different developmental commitment stages into beta-like cells 
through overexpressing Pdx1, Ngn3 and MafA. We used mouse hepatocyte-derived small 
cells (ASH), mouse primary hepatocytes, mouse embryonic fibroblasts (MEF) and mouse 
adult (tail tip) fibroblasts, rat primary hepatocytes, rat pancreatic exocrine cells (AR42J-
B13), rat adult fibroblasts (CRL-1213) and rat multipotent adult progenitor cells 
(MAPC).  
 
1.2. Experimental Design and Methods 
 
1.2.1. Preparation of Recombinant Adenovirus  
We constructed a single adenoviral vector coding three important pancreatic 
transcription factors; PDX1, NGN3 and MAFA from mouse and called it Ad-PNM 
(Figure 4). The translational termination sequences of the full length mouse Pdx1 and 
Ngn3 cDNAs were replaced with specific restriction sites by using polymerase chain 
replication (PCR). Amplified cDNAs were then cloned into pBluescript (KS+/-) as 
XbaI/BamHI fragments. pBS-Pdx1-2A and pBS-Ngn3-2A constructs were generated by 
ligation of Pdx1 and Ngn3 cDNAs to the coding region for the 2A peptide, which 
includes 18 amino acids, from the Foot and Mouth Disease Virus (FMDV). These two 
constructs were then joined together such that the coding region of the Pdx1-linked 2A 
was followed by the first amino acid codon of the Ngn3 so that giving the construct pBS-
Pdx1-2A-Ngn3-2A. This construct was then ligated to the MafA cDNA which is including 
its own the translational termination codon and cloned as BglII/EcoRV fragment in 
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pBluescript (KS+/-) to generate the polycistronic construct pBS-Pdx1-2A-Ngn3-2A-MafA. 
Pdx1-2A-Ngn3-2A-MafA construct was taken out as a single fragment by restriction 
digestion via SalI enzyme, the target sites of which locates internally upstream of Pdx1 
and downstream of MafA, and cloned into the shuttle vector, pShuttleT2ALCAG5PL4-7. 
Recombinant adenovirus containing Pdx1-2A-Ngn3-2A-MafA construct was produced by 
homologous recombination after electroporating the linearized shuttle vector into BJ5183 
bacterial cells. This was done by using the pAdEasy adenoviral vector system (Agilent 
Technologies) according to the manufacturer's instructions.  
 
1.2.2. In Vitro Culture of Cell Lines and Transfection with Ad-PNM 
Mouse hepatocyte-derived small cells (ASH), which were derived from a primary 
mouse hepatocyte culture in vitro, were obtained from Dr. David Tosh (University of 
Bath, UK). ASH cells were maintained in low-glucose Dulbecco`s Modified Eagles 
medium (DMEM; Gibco) supplied with 10% (v/v) fetal bovine serum (FBS; Hyclone) 
and 1x antibiotic-antimycotic solution (anti-anti; Gibco). 
Mouse embryonic fibroblasts (MEF) were isolated from prenatal mouse embryos. 
MEF cells were maintained in high-glucose DMEM supplied with 10% (v/v) FBS, 2mM 
L-glutamine (Gibco) and 1x anti-anti solution. 
Mouse adult fibroblasts were obtained by culturing a piece of tail tip from an 
adult mouse in vitro. These tail tip-derived mouse adult fibroblasts were maintained in 
high-glucose DMEM supplied with 10% (v/v) FBS, 2mM L-glutamine and1x anti-anti 
solution. 
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Rat primary hepatocytes were isolated from adult male rats by two-step 
collagenase perfusion method described in (Seglen 1976). After the isolation rat primary 
hepatocytes were cultured in William`s E medium (Gibco) supplied with 10% (v/v) FBS, 
2mM L-glutamine, 1x anti-anti and gentamycin solution (Gibco) overnight for 
attachment to plate. After cells attached to the plate they were maintained in low-glucose 
DMEM supplied with 10% (v/v) FBS, 2mM L-glutamine and 1x anti-anti solution. 
Rat pancreatic exocrine-like cells (AR42J-B13), which were originally derived 
from a chemically induced pancreatic tumor (Longnecker, Lilja et al. 1979) were 
obtained from Dr. David Tosh. 
Rat adult fibroblast cells (CRL-1213) were bought from ATCC and were 
maintained in high-glucose DMEM supplied with 10% (v/v) FBS, 2mM L-glutamine and 
1x anti-anti solution. 
Rat multipotent adult progenitor cells (MAPC), which were originally isolated 
from bone marrow and shown to have progenitor cell characters (Schwartz, Reyes et al. 
2002), were obtained from Wei-Shou Hu`s Laboratory (University of Minnesota, MN). 
MAPCs were maintained in low-glucose DMEM and MCDB medium (Sigma) supplied 
with 2% (v/v) FBS, 1x anti-anti solution, 1x ITS (Insulin/Transferrin/Selenium; Sigma), 
1mg/ml LA-BSA (Linoleic acid-bovine serum albumin; Sigma), 1x L-ascorbic acid, 
0.5µM dexamethasone, 10ng/ml PDGF (Platelet-derived growth factor; Sigma), 10ng/ml 
EGF (Epidermal growth factor; Millipore), 0.01x LIF (Leukemia inhibitory factor; 
Millipore) and 0.1x β-mercaptoethanol (Gibco).  
All the cell types were transduced with a dose of 25 multiplicity of infection 
(MOI) Ad-PNM. Next day the virus containing medium was replaced. Three days after 
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virus transduction, total RNA was isolated for reverse transcription–polymerase chain 
reaction (RT-PCR) and the cells were also fixed for immunostaining to see how they had 
responded. 
 
1.2.3. Reverse Transcription–Polymerase Chain Reaction (RT-PCR)  
Total RNA from the cells was isolated using the RNeasy Mini Kit (Qiagen) 
according to the manufacturer's manual. RNA samples were then treated with DNase 
enzyme (Promega) to remove possible genomic DNA contamination. A PCR was 
performed with the RNA template at 60◦C for 35 cycles and resulting products were run 
on 1% agarose gel to confirm the absence of genomic DNA contamination. cDNAs were 
then synthesized by reverse transcription from 2μg total RNA using SuperScript III 
Reverse Transcriptase, oligo(dT)20 and dNTP (10mM) (Invitrogen). The gene expression 
pattern between the cells with and without Ad-PNM was then compared by performing 
PCR. PCR conditions were: 94◦C 3 min initial denaturation, 94◦C 30 s denaturation, 60◦C 
30 s annealing, 72◦C 1 min extension, 72◦C 5 min final extension and overall 30-35 cycles 
were performed. Primers used for RT-PCR are listed in Table 1. PCR products were then 
run on 1% (w/v) agarose gel (Invitrogen), in TAE (Tris-Acetic Acid-EDTA) buffer (Bio-
Rad Laboratories) including ethidium bromide, by electrophoresis at 100V. Gels were 
visualized with a Bio-Rad Gel Documentation System model 2000.  
 
1.2.4. Immunostaining  
The cells were fixed with 4% (w/v) paraformaldehyde (Sigma) in PBS (Phosphate 
buffered saline; Sigma) for 20 min. After fixation cells were washed three times with 
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0.1% (v/v) Tween 20 (Bio-Rad) in PBS (PBS-T) for 5 min in each wash. Cells were then 
permeabilized with 0.2% (v/v) Triton X-100 (Sigma) in PBS for 15 min. After 1 hour 
blocking with PBS-T including 1% (w/v) BSA (Bovine serum albumin; Sigma), cells 
were incubated overnight with primary antibodies at 4◦C and then 1 hour with secondary 
antibodies at room temperature. Primary antibodies used were as follows: guinea pig anti-
insulin (1:200 dilution, Sigma); rabbit anti-Pdx1 (1:2000 dilution, Upstate); rabbit anti-C-
peptide (1:100 dilution, Cell Signaling), rabbit anti-Ngn3 (1:100 dilution, Santa Cruz 
Biotechnology); and rabbit anti-MafA (1:100 dilution, Santa Cruz Biotechnology). 
Secondary antibodies used are as follows: alexa fluor 480 goat anti-rabbit IgG (1:500 
dilution, Invitrogen) and alexa fluor 594 goat anti-guinea pig IgG (1:500 dilution, 
Invitrogen). Images were taken using a Leica DMI6000 B inverted microscope.  
 
1.3. Results 
When cultured cells are transduced with three adenoviruses carrying different 
genes, individual cells may receive one, two or three genes randomly. To remove this 
source of variation we have designed an adenoviral vector carrying all three genes in 
order (Figure 4). The coding regions of Pdx1, Ngn3 and MafA are joined by 2A 
sequences, which are responsible from autocleavage of the extending polypeptide during 
protein synthesis (de Felipe 2004). The whole construct is under control of the highly 
active cags (cytomegalovirus-chicken β-actin) promoter (Chung, Andersson et al. 2002). 
This vector (Ad-PNM) was shown to infect almost all of the cells efficiently and 
expression of all three exogenous proteins was detected by immunostaining (Figure 10). 
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Three days after Ad-PNM induction, in all eight cell types used in this study 
Insulin genes (there are two different insulin genes in rodents: Ins1 and Ins2) expression 
was detected in the RT-PCR but at varying intensities. In addition to Insulin, the most 
responsive four cell types (rat primary hepatocytes, rat MAPCs, AR42J-B13 cells and 
ASH cells) also activated some other important beta cell markers with different 
expression patterns (Figure 5). After Ad-PNM induction, rat primary hepatocytes started 
to express alpha cell hormone gene glucagon (Gcg), beta cell transcription factor genes 
Iapp (Islet amyloid polypeptide), Pax4, Isl1, Mnx1, beta cell membrane protein genes 
Slc2a2, Kcnj11 (Potassium inwardly rectifying channel subfamily J member 11; also 
known as Kir6.2), and Abcc8 (ATP-binding cassette sub-family C CFTR/MRP member 8; 
also known as Sur1), endogenous counterparts of Pdx1 and MafA as well as Cpe 
(Carboxypeptidase E) (Figure 5A). Rat MAPCs expressed beta cell transcription factor 
genes Iapp, Pax4, Neurod1, Nkx2.2, Isl1, Mnx1, beta cell membrane protein genes 
Slc2a2, Kcnj11 and Abcc8 (Figure 5B). AR42J-B13 cells expressed beta cell transcription 
factor genes Iapp, Pax4, Neurod1, Nkx2.2, beta cell membrane protein gene Abcc8 as 
well as Cpe and Pcsk2 (Figure 5C). ASH cells began to express Pp-cell hormone gene 
Pancreatic polypeptide (Ppy), beta cell transcription factor genes Iapp, Pax4, Mnx1, beta 
cell membrane protein genes Slc2a2, Kcnj11 and Abcc8 as well as Cpe and Pcsk2 
(Proprotein convertase subtilisi/kexin type 2; also known as PC2) (Figure 5D). However 
none of these cell types activated the entire group of beta cell genes likely to be necessary 
for beta cell function. In addition to activating some of the beta cell genes, these cells also 
downregulated the expression of some of their original genes like Pou5f1 (POU domain 
class 5 transcription factor 1; also known as Oct4) in Rat MAPCs, Pancreatic amylase 
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(Amy2) in AR42J-B13 cells, Albumin (Alb) in ASH cells. The other four cell types which 
are rat adult fibroblasts (CRL-1213), mouse embryonic fibroblasts, mouse primary 
hepatocytes and mouse adult (tail tip) fibroblasts showed little or no response in a 
majority of the beta cell genes apart from Insulin (Figure 5E, 5F, 5G, 5H). 
Although Insulin genes were detected for all the cell types in RT-PCR, insulin 
immunostaining was only detected in five cell types which are rat primary hepatocytes 
(Figure 6A-A`), ASH cells (Figure 6B-B`), AR42J-B13 cells (Figure 6C-C`), rat MAPCs 
(Figure 6D) and CRL-1213 (Figure 6E). In addition to insulin, expression of C-peptide, 
which is a side product formed during proinsulin to insulin transition, and its co-
localization with insulin in the same cells, were also shown for rat primary hepatocytes 
(Figure 6A`-A``), ASH cells (Figure 6B`-B``) and AR42J-B13 cells (Figure 6C`-C``).  
Based on these results we concluded that the transformation competency of the 
cells into insulin expressing beta cell-like state is higher for a) rat cell lines compared to 
mouse cell lines; b) progenitor-like cell lines compared to the terminally differentiated 
cell lines; and c) cells which are developmentally related to beta cells such as hepatocytes 
and acinar cells compared to the developmentally unrelated cell lines such as fibroblasts.  
 
1.4. Discussion 
Three days after transduction with Ad-PNM, all cell types used in this study 
showed Insulin genes activation in RT-PCR at various intensities. In addition to the 
Insulin genes, some other beta cell genes were also activated in four cell types: rat 
primary hepatocytes, ASH cells, rat MAPCs and AR42J-B13 cells. However none of 
these cell types activated all the important beta cell genes. After transduction with Ad-
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PNM, rat primary hepatocytes lacked Nkx2.2 and Neurod1 expression; ASH cells lacked 
Neurod1, Nkx2.2, Isl1, endogenous Pdx1 and endogenous MafA expression; rat MAPCs 
lacked endogenous Pdx1 and endogenous MafA expression; AR42J-B13 cells lacked Isl1, 
Mnx1, endogenous Pdx1, endogenous MafA, Slc2a2 and Kcnj11 expression.  
Activation of Insulin genes together with some other beta cell markers shows the 
ability of the Pdx1, Ngn3 and MafA combination to lead the transformation of different 
cell types into beta cell-like state. Downregulation of the major product genes in the 
recipient cells also supports this theory. Immunocytological detection of the co-existence 
of C-peptide together with insulin protein in the same cells also demonstrated that 
detectable insulin expression was coming from the transformed cells rather then being 
tissue culture medium insulin which can be absorbed by dead and/or dying cells. On the 
other hand, the absence of essential beta cell genes such as Kcnj11, Abcc8 and Slc2a2, as 
well as endogenous counterparts of input genes, showed that the transformation into a 
beta cell-like state was not complete. In real beta cells, the insulin amount to be released 
into the blood stream is adjusted according to glucose amount in the blood. This glucose 
dependent insulin release function of beta cells is controlled by KCNJ11, ABCC8 as well 
as SLC2A2 membrane proteins. This is why these proteins are indispensable for a true 
beta cell phenotype. Moreover, in adult beta cells Pdx1 and MafA are master genes 
driving Insulin gene expression as well as other beta cell transcription factors. To obtain a 
true beta cell phenotype endogenous Pdx1 and MafA should be activated and stay on after 
the removal of their exogenous counterparts. In our experiments none of the cell types 
were transformed into true beta cells because they did not fulfil two requirements 
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mentioned above: a) all of the genes of the cell type of interest should be activated; and 
b) the endogenous counterparts of input genes (if any used) should be activated.  
In this study we used eight different cell lines from two different species: rat and 
mouse. Based on the response of these cell types against Pdx1, Ngn3 and MafA 
combination, our overall observation was that rat cell types no matter what their 
developmental stage are transformed better than their mouse counterparts. In mouse 
primary hepatoytes, for instance, only Ins1 and Gcg genes were activated (Figure 5G). 
However, rat primary hepatocytes activated more beta cell genes after transduction with 
Ad-PNM (Figure 5A). Comparison of rat and mouse fibroblasts gave a similar result. 
While mouse adult (tail tip) fibroblasts were activating Ins2 and Iapp genes only (Figure 
5H), rat adult fibroblasts activated Ins1, Ins2, endogenous Pdx1 and Kcnj11 genes 
(Figure 5E). Immunocytologic detection of insulin protein was also achieved in rat 
fibroblast cells unlike mouse tail tip fibroblast cells. Of the mouse cell lines we used in 
this study, only mouse hepatocyte-derived small cells (ASH) showed a significant 
response to Ad-PNM (Figure 5D). We conclude that this was due to the progenitor cell-
like phenotype of these ASH cells. Similar to the ASH cells response, rat MAPCs, a 
progenitor cell type, activated more beta cell genes after transduction with Ad-PNM than 
rat fibroblast cells did (Figure 5B and 5E). On the other hand, even though rat primary 
hepatocytes and rat pancreatic exocrine cell line AR42J-B13 cells are not progenitor-like 
cells, they showed a significant response to Ad-PNM by activating many beta cell genes 
(Figure 5A and 5C). Our results suggest that the competency of these two cell types to 
give rise to a beta cell-like state is due to their developmental relatedness to beta cells. 
During embryogenesis of the liver, the principal functional cell type of which is the 
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hepatocyte, and the pancreas, arise from neighboring regions of the same embryonic 
tissue, the definitive endoderm. Different signals from surrounding tissues like FGFs 
from the cardiac mesoderm (Jung, Zheng et al. 1999) and BMP from the septum 
transversum (Rossi, Dunn et al. 2001), and activin-βB and FGF2 from the notochord 
(Kim, Hebrok et al. 1997) directs the formation of liver and pancreatic buds respectively 
from definitive endoderm. For that reason hepatocytes and beta cells should share a 
similar epigenetic memory to a large extent. Similarly, pancreatic exocrine and endocrine 
cells arise from a same progenitor cell population during pancreas development (Percival 
and Slack 1999) and they should share a similar epigenetic memory which makes them 
more competent to be transformed into each other than any other unrelated cell types. 
Even though rat primary hepatocytes and the rat pancreatic exocrine cell line AR42J-B13 
did not activate all important beta cell genes after transduction with Ad-PNM, their 
higher response supports the transformation competency theory of developmentally 
related cells mentioned above.  
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Figure 4: Structure of adenovirus carrying Pdx1, Ngn3 and MafA (Ad-PNM). 
Pdx1, Ngn3 and MafA are linked to each other respectively through 2A sequence which 
provides autocleavage of extending polypeptide during protein synthesis. The whole 
construct is under the control of cags promoter.  
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Figure 5: Gene expression profile of different cell types after Ad-PNM (RT-PCR) 
Different cell types from mouse and rat were transduced with Ad-PNM. Gene expression 
profile of most responding cell types: (A) Rat primary hepatocytes, (B) Rat MAPCs, (C) 
AR42J-B13 cells, (D) ASH cells and cells showing little or no response: (E) Rat adult 
fibroblasts, (F) Mouse embryonic fibroblasts, (G) Mouse primary hepatocytes, (H) 
Mouse adult fibroblasts were shown by RT-PCR. 30 cycles of PCR were performed for 
each primer pairs unless it is stated next to gene name.
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Figure 6: Insulin and C-peptide immunostaining in different cell types after Ad-
PNM 
Different cell types from mouse and rat were transduced with Ad-PNM. 3 days after Ad-
PNM transduction expression of insulin protein (red) in (A-A`) Primary rat hepatocytes, 
(B-B`) ASH cells, (C-C`) AR42J-B13 cells, (D) Rat MAPCs and (E) Rat fibroblasts were 
demonstrated through immunostaining. Expression of C-peptide (green) in (A``) Primary 
rat hepatocytes, (B``) ASH cells and (C``) AR42J-B13 cells was also demonstrated. 
Insulin expression was detected only in viral PDX1 (green) expressing cells (A, B, C, D, 
E).  
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Table 1: Rat and mouse primer pairs used in RT-PCR 
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Rat Primers used in RT-PCR 
Primer 
name Forward Sequence 5`-3` Reverse Sequence 5`-3` 
Ins1 CTACAATCATAGACCATCAGCA CAGTTGGTAGAGGGAGCAGAT 
Ins2 CCCTGTGGATCCGCTTCCTGC  GTGCCAAGGTCTGAAGGTCA 
Gcg  GCTGGCAGCATGCCCCTCAA CCTTTGCTGCCTGGCCCTCC 
Ppy CTATCCACTTGGGTGGCTCT ATCAAACCCACCAGAAGGC 
Sst CCCAGACTCCGTCAGTTTCT GAAGTTCTTGCAGCCAGCTT 
Iapp GGCTGTAGTTCCTGAAGCTT AAGGTTGTTGCTGGAGCGAA 
Pax4 TGGAGAAAGAGTTCCAGCGT CTTGGGATGTGGTGTCACTG 
Neurod1 TTTCAAACACGAACCATCCA CCTGTTTCTTCCAAAGGCAG 
Nkx2.2  CACGCGCTCAAAGCCCAGGA GGAGAGAGCGGTGGGGCAGA 
Arx  AGGACGCCGAGGGCAAGGAT TCTCCCGCTTGCGCCACTTG 
Pdx1 GTAGTAGCGGGACAACGAGC CAGTTGGGAGCCTGATTCTC 
Ngn3 AAACTTCGAAGCGAGCAGAG CATCCTGAGGTTGGGAAAAA 
MafA TCCAGGCTGGTGCGCGAAAG GCAAGCCCACTCAGGAGCCG 
Isl1 TGATGCGCGCCCGCTCTAAG TGACTCGGGGACTGAGGCCG 
Mnx1 CCTGTCGCGACCCAAGCGTT CCCAGCAGCTCCTCCTCCGT 
Pax6 GGCCGTGCGACATTTCCCGA GCCGTCTGCGCCCATCTGTT 
Hes1 GGCCACCTGGCCAACTGCAT GCTGGAAGGCGACACTGCG 
Slc2a2 GCCATCTTCCTCTTCGTCAG ACCTGGTTCCCTTCTGGTCT 
Kcnj11 CTGGAAGGAAGCCAGTCTTG CAGTGTCCCCCAGACAAAGT 
Abcc8 AGCTGCGCTTCTGCCTCACG GGCACCCTGCTGGCTCTGTG 
Amy2a GCCTACTGACAGAGCCCTTG TGGTCCAATCCAGTCATTCA 
Ptf1a CCTCTCCAAGGTAGACACGC CTTGGGATGTGGTGTCACTG 
Cpe  GACCGGCGGTACAGCTCGCG CTGCGCCCCACCGTGTAGAT 
Pcsk2 ACACAGCTCCGCACATTCGCA TGAGATCCACAACCGCCCTCCA 
Prss1 GTGTATCCTCCAACGATCTTGT CACTTCTGATCCTAGCCCTTG 
Cpa1 CCAGAAGTCCAACTGCAAGT CAGTCTGTGGCAATGAGAACT 
Ctrb1 GAATAGCATCCTCTCCGTTGAC GTCCTGCTTTGCCCTTGT 
Rbpjl CATCTCCGAACCACACCTTG CTCCAGTGCCTCATATCAGC 
Actb TCCGTAAAGACCTCTATGCC GGAGGGGCCGGACTCATCGT 
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Mouse Primers used in RT-PCR 
Primer 
name Forward Sequence 5`-3` Reverse Sequence 5`-3` 
Ins1 TAGTGACCAGCTATAATCAGAG ACGCCAAGGTCTGAAGGTCC 
Ins2 CCCTGCTGGCCCTGCTCTT  AGGTCTGAAGGTCACCTGCT 
Gcg  TGTCTACACCTGTTCGCAGC TCCTCATGCGCTTCTGTCTG 
Ppy GGCCCAACACTCACTAGCTC CTGCTCAGGTGTCGCATAGT 
Sst GGACCTGCGACTAGACTGAC GGCTCCAGGGCATCATTCTC 
Iapp CGTTCCAGCAACAACCTTGG CCCTATTTGGATCCCCTGCC 
Pax4 CCACCTCTCTGCCTGAAGAC CCCACAGCATAGCTGACAGA 
Neurod1 GCCTTTACCATGCACTACCC CCCGGGAATAGTGAAACTGA 
Nkx2.2  AGCGACAACCCCTACACTCGC GCCTGAGTCAGTCGCCCGAC 
Arx  TCTCTTCCTCCGGATACCCC GATTCGCATTCGCTTCCCTG 
Ngn3 CCGGATGACGCCAAACTTACA ACACCAGTGCTCCCGGGAG 
Pdx1 CCGGACATCTCCCCATACGAAGT CGCACAATCTTGCTCCGGCTCT 
MafA ATCATCACTCTGCCCACCAT AGTCGGATGACCTCCTCCTT 
Isl1 CACTATTTGCCACCTAGCCAC AAATACTGATTACACTCCGCAC 
Mnx1 CTCATCTGAGGACGACTCGC CCAGGTAGCCATCTTTCGCA 
Pax6 CGTTGACATTTAAACTCTGGGGC CAGCACCTGGACTTTTGCAT 
Hes1 GAGGCTGCCAAGGTTTTTGG ACTTTACGGGTAGCAGTGGC 
Slc2a2 CGACCAGGAGGAACCACGCG TGAGCCTTGCTGACACCAGCC 
Kcnj11 CAAGATGCACTTCAGGCAAAA ACGATGTCTGGTGGATGTCA 
Abcc8 CCTGCAGCCAGACATAGACA GCTCTTGGTCTTGCCTGTTC 
Afp ACTCACCCCAACCTTCCTGTC CAGCAGTGGCTGATACCAGA 
Alb CAGATGACAGGGCGGAACTT AGGTGCTTTCTGGGTGTAGC 
Chga AGCCAGACTACAGACCCACT TGACTTCCAGGACGCACTTC 
Ptf1a TCAGCGAGCTGGTGCAAGCC AAGACGCGGCCAACCCGATG 
Pcsk1 CACAGACCAGCGAATAACAA AGCAAAGATACCAGCAGCCA 
Pcsk2 AAGAAGACGCAGCCTACACC TTGTATGCTACGCCGACTCC 
Cpe TTTTCCAAAGCTTGGCTCGC TGTGATTGCCAGGTAGCCAG 
Actb GCAGCTCCTTCGTTGCCGGT TACAGCCCGGGGAGCATCGT 
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Chapter 2 Investigation the Effect of Ad-PNM on Mouse Embryonic Hepatoblasts 
(E14-16) 
 
2.1. Introduction 
Developmental relatedness of liver and pancreas makes liver cells one of the best 
candidates for beta cell formation studies. It is likely that the competence of relevant 
genes to be upregulated depends on their chromatin configuration and this will be more 
similar the closer the developmental lineage (Slack 2007). In vitro formation of insulin-
positive cells with expression of other beta cell markers from Ad-PNM transduced rat 
primary hepatocytes shown in Chapter B1 also supports this idea. In addition, we also 
showed (Chapter B1) that progenitor-like cells are more susceptible to be reprogrammed 
into beta-like cells than differentiated cells. Based on these two facts, we investigated 
how efficiently mouse embryonic (E14-16) hepatoblast cells can be reprogrammed into 
insulin expressing beta-like cells through Ad-PNM transduction. For this purpose we 
used CD1 mice and Pdx1-GFP transgenic mice in which GFP protein is under control of 
the Pdx1 promoter.  
 
2.2. Experimental Design and Methods 
 
2.2.1. Isolation and Ad-PNM Transduction of E14-16 Mouse Hepatoblasts 
Mouse embryos from Pdx1-GFP transgenic mice and/or CD1 mice were 
harvested at 14-16 dpc. Livers were excised from embryos and minced into small pieces 
in 0.5mg/ml collagenase (Worthington) enzyme. After 30 min incubation at 37◦C liver 
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tissues were dissociated into single cells by pipeting and passed through a 100μm 
membrane. Dissociated embryonic hepatoblasts were plated on collagen (Invitrogen) 
coated plates and maintained in high glucose DMEM supplemented with 10% FBS and 
1x anti-anti solution. The next day cells were transduced with 25moi Ad-PNM and the 
virus was removed the day after transduction by changing the medium.  
 
2.2.2. Immunostaining 
Five days after the Ad-PNM transduction cells were fixed and stained as 
described in Chapter B1. Primary antibodies used were as follows: guinea pig anti-insulin 
(1:200 dilution, Sigma); rabbit anti-Pdx1 (1:2000 dilution, Upstate); rabbit anti-C-peptide 
(1:100 dilution, Cell Signaling); and mouse anti-E-cadherin (1:250 dilution, BD 
Bioscience). Secondary antibodies used were as follows: alexa fluor 480 goat anti-rabbit 
IgG (1:500 dilution, Invitrogen), alexa fluor 594 goat anti-guinea pig IgG (1:500 dilution, 
Invitrogen) and alexa fluor 488 anti-mouse IgG (1:500 dilution, Invitrogen). Images were 
taken using a Leica DMI6000 B inverted microscope. 
 
2.2.3. Fluorescence Activated Cell Sorting (FACS) of GFP Positive Cells 
Five days after the Ad-PNM transduction, cells from Pdx1-GFP transgenic mouse 
were dissociated from tissue culture plates with TryplE and were collected into FACS 
tubes. 7-Aminoactinomycin D (7-ADD) was also added into the cell suspension to label 
and thereby exclude dead cells during cell sorting. For gating, cells with no Ad-PNM 
were used as negative control. GFP positive cells were then sorted with a FACS Aria.  
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2.2.4. qRT-PCR 
Total RNA isolation and cDNA synthesis from GFP-positive sorted cells (5 days 
in culture) control cells (no Ad-PNM, 5 days in culture) and E14-16 hepatoblasts (after 
isolation, not cultured in vitro) were performed as described in Chapter B1. The gene 
expression pattern between GFP-positive cells, 0 and 5 day control was then compared by 
performing qRT-PCR for mouse Alb, Alpha fetoprotein (Afp), Transferrin (Trf), Hnf4a, 
Ins1, Ins2, Gcg, Somatostatin (Sst), Ppy, endogenous Pdx1, Pdx1, Ngn3, MafA, Kcnj11, 
Abcc8, Insm1, Slc2a2, Neurod1, Pax4, Rfx6, Isl1, Gck, Pcsk1, Pcsk2, Cpe, Nkx2.2, 
Nkx6.1, Mnx1, Solute carrier family 30 (zinc transporter) member 2 (Slc30a2), Arx, 
Amy2, and Glyceraldehyde-3-phosphate dehydrogenase (Gapdh). After an initial 
denaturation at 95◦C for 30 s, reaction mixtures were subjected to 40 cycles of 
amplification using the following conditions: 95◦C for 5 s denaturation, and 60◦C for 10 s 
annealing and extension. The primer pairs used for the qRT-PCR are listed in Table 2. 
 
2.2.5. ELISA for Glucose-Stimulated Insulin Release 
After sorting the Ad-PNM treated GFP-positive E14-16 hepatoblasts of Pdx1-
GFP transgenic mouse, the cells (~105) were incubated in KRB (Krebs–Ringer buffer) 
supplemented with 2.8mM (low glucose environment) and then in 20mM (high glucose 
environment) glucose for 1 h at 37◦C in each, respectively. For the control cells, E14-16 
hepatoblasts cultured in vitro without Ad-PNM were used. The KRB was then removed 
and kept at −80◦C. The amount of insulin released into the medium was measured using 
an Ultrasensitive Mouse Insulin ELISA kit (Mercodia), according to the manufacturer’s 
instructions.  
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2.3. Results 
 
2.3.1. CD1 Mouse 
Experiments performed with CD1 mouse E14 embryos showed that after the 
isolation some hepatoblasts were completely dissociated into single cells whereas some 
of them remained as cell clusters (Figure 7A). After plating on collagen coated plates 
these hepatoblast clusters layered immediately and grew as distinct colonies among the 
mesenchymal cells (Figure 7B). Immunostaining for insulin protein showed that some 
cells within these colonies start to express insulin 5 days after Ad-PNM transduction 
(Figure 7C and D). C-peptide was also shown to colocalize with insulin (Figure 7D and 
D`). E-cadherin is a hepatoblast marker (Nitou, Sugiyama et al. 2002) and 
immunostaining demonstrated that cells expressing insulin were no longer E-cadherin 
positive (Figure 7E). However insulin negative cells were still positive for E-cadherin.  
 
2.3.2. Pdx1-GFP Mouse 
Transduction of Pdx1-GFP transgenic mouse E14-16 hepatoblasts with Ad-PNM 
resulted in the expression of GFP in some cells 5 days after Ad-PNM transduction 
(Figure 8A). Even though the fraction of GFP-positive cells (1%) was low, we sorted 
nearly 105 cells out of 107 cells. From these sorted cells we performed qRT-PCR to 
identify the gene expression profile and ELISA to examine glucose stimulated insulin 
release of the cells. We also performed immunostaining on a sample of these cells before 
we sorted them. 
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Immunostaining of these cells showed that not all but some of these GFP-positive 
cells were also insulin positive (Figure 8B and C). Also there were some cells which were 
positive for insulin but not GFP. 
The qRT-PCR of GPF-positive cells showed that these cells upregulated many 
pancreatic endocrine cell markers including the islet hormone genes Ins1, Ins2, Gcg, Sst, 
Ppy, glucose stimulated insulin release-related cell membrane protein genes Kcnj11, 
Abcc8, Slc2a2, insulin maturation-related protein genes Pcsk1, Pcsk2, Cpe, and beta cell 
transcription factors such as endogenous Pdx1, Neurod1, Pax4, Rfx6, Isl1, Insm1 (Figure 
9). Moreover GFP-positive cells downregulated the expression of liver markers such as 
Alb, Afp, Trf and Hnf4a to some extent although not completely (Figure 9). However 
GFP-positive cells are still missing some typical beta cell transcription factors such as 
Nkx2.2, Nkx6.1 and Mnx1.  
ELISA results showed that Ad-PNM transduced GFP-positive cells can secrete 
insulin and that the release of insulin was to some degree controlled by the glucose level 
(Figure 10). Hepatoblast cells cultured for 5 days with no Ad-PNM transduction had trace 
amounts of insulin released into the medium. Ad-PNM transduced GFP-positive cells, 
however, increased the amount of released insulin in low glucose and even more in high 
glucose environments (Figure 10). 
 
2.4. Discussion 
The qRT-PCR results showed that the GFP-positive cells have indeed upregulated 
the endogenous Pdx1 gene, and were not simply showing a false-positive upregulation of 
GFP (Figure 9). This is the first time that we have seen the upregulation of endogenous 
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Pdx1 in mouse cells. The activation of endogenous counterparts of the input genes is 
essential for real reprogramming events. Otherwise even if target genes are upregulated, 
the cells remain dependent on input genes to maintain their new phenotype. Beside 
endogenous Pdx1, the GFP-positive cells upregulated also other important beta cells 
markers such as beta cell hormone genes (Ins1 and Ins2), insulin processing protein genes 
(Pcks1, Pcsk2 and Cpe), beta cell membrane protein genes responsible for glucose 
stimulated insulin release (Kcnj11 and Abcc8) and many beta cell transcription factors 
(Neurod1, Pax4, Isl1, Isnm1, Rfx6). Moreover liver cell markers such as Alb, Afp, Trf and 
Hnf4a were downregulated in these cells. However even though the effects of Ad-PNM 
on these cells were dramatic, these cells were not fully reprogrammed into genuine beta 
cells. Beside Insulin genes, the expression of Gcg, Ppy and Sst encoding other pancreatic 
hormones, indicates that this was not a true beta cell phenotype. Moreover, even though 
the liver markers were downregulated significantly, they were not completely turned off. 
A modest degree of glucose stimulated insulin release was shown by the GFP-
positive cells. This glucose dependent insulin release of GFP-positive cells was consistent 
with the observed Kcnj11 and Abcc8 upregulation. Even though the results are 
encouraging, the amount of released insulin was still lower than insulin amount released 
by genuine beta cells. 
The results indicate that the embryonic hepatoblasts are more susceptible to the 
effects of Ad-PNM than adult hepatocytes. Although the transformation to a beta cell 
phenotype was not complete, it should be noted that the GFP-positive population 
contained many cells which were not insulin positive and may represent other types of 
pancreatic precursors. It is therefore possible that the minority of insulin-positive, GFP-
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positive cells do have a genuine beta cell phenotype, although to establish this for sure 
would require considerable additional work.  
  57 
Figure 7: Insulin, C-peptide and E-cadherin immunostaining in CD1 mouse 
embryonic hepatoblasts after Ad-PNM 
(A) Hepatoblast cell clusters immediately after isolation from E14-16 mouse embryo, (B) 
Expanding hepatoblasts in culture 1 day after isolation, (C) Insulin (red) and viral PDX1 
(green) positive hepatoblasts 5 days after Ad-PNM transduction, (D) Insulin (red) and 
(D`) C-peptide (green) colocalization in the same cells, (E) Expression of Insulin (red) 
and E-cadherin (green) in different cells. DAPI (blue). Scale bars =100μm. 
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Figure 8: GFP expression and insulin immunostaining in Pdx1-GFP mouse 
embryonic hepatoblasts after Ad-PNM 
GFP expression (A) and Insulin (red) staining (B, C) in mouse embryonic hepatoblasts 
(E14-16) 5 days after Ad-PNM transduction. Scale bars =100μm.
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Figure 9: Gene expression profile of E14-16 mouse embryonic hepatoblasts after 
Ad-PNM (qRT-PCR)  
Gene expression profile between day 0 E14-16 mouse hepatoblasts (immediately after 
isolation, No Ad-PNM) (white bars), day 5 E14-16 mouse hepatoblasts (cultured 5 days 
in vitro, No Ad-PNM) (gray bars) and GFP-positive FACS sorted E14-16 mouse 
hepatoblasts (cultured 5 days in vitro, transduced with Ad-PNM) (black bars) were 
compared with qRT-PCR. Top panel is showing the expression pattern of pancreatic 
markers. Bottom panel is showing the expression pattern of liver markers. Data are 
means ± S.E. (n = 3).
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Figure 10: Secreted insulin from E14-16 mouse embryonic hepatoblasts after Ad-
PNM 
The amount of insulin in the medium released from E14-16 mouse hepatoblasts (cultured 
5 days in vitro, No Ad-PNM) and GFP-positive FACS sorted E14-16 mouse hepatoblasts 
(cultured 5 days in vitro, transduced with Ad-PNM) was measured by ELISA. GFP-
positive cells were stimulated either with low-glucose or high-glucose. Data are means ± 
S.E. (n = 2). 
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Table 2: Mouse primers used in qRT-PCR 
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Mouse Primers used in qRT-PCR 
Primer 
name Forward Sequence 5`-3` Reverse Sequence 5`-3` 
Alb CAGTCAGCCAGTTCACCATAG TGTGTTGCCGATGAGTCTG 
Ins1  GCCATGTTGAAACAATGACCTG  GCCAAACAGCAAAGTCCAG 
Ins2  CATGGGTGTGTAGAAGAAGCC TTTGTCAAGCAGCACCTTTG 
Gcg  CAGCATGCCTCTCAAATTCATC  ACATTCACCAGCGACTACAG       
Sst GGCATCATTCTCTGTCTGGTT AGACTCCGTCAGTTTCTGC 
Ppy GCTGGACCTGTACTCTCCTA TTGGCTTGATTCCCTGCTC 
Amy2 TCTCTGTGTTGGAAAATGAAATCT   CCTGGAGACATAAAGGCAGTT 
Pdx1 GCAGTACGGGTCCTCTTGT GATGAAATCCACCAAAGCTCAC 
MafA GCCAACTTCTCGTATTTCTCCT CACATTCTGGAGAGCGAGAAG 
Pax4 AGAAGCTGAAATGGGAAGCA GGGGACTGTGCAGAGATGAT 
Nkx2.2 CTTATCCAATCGCTCCACCTT TCCAGAACCATCGCTACAAG 
Nkx6.1 TCCGAGTCCTGCTTCTTCT CACGCTTGGCCTATTCTCTG 
Rfx6 CAATAAATGCCTCCACTGTAGC TCTTACCATATCCAACAGCACA 
Isl1 GCCTGTAAACCACCATCATGT GTGCAAGGACAAGAAACGC 
Mnx1 GCTGCGTTTCCATTTCATTCG CAGTTCAAGCTCAACAAGTACC 
Neurod1 ACACTCATCTGTCCAGCTTG AGATCGTCACTATTCAGAACCTTT 
Arx TGTGGGCTGTCTCAGGA  GGTCTGAGCACTTTTCTAGGAG 
Abcc8 GAATGATGACAGCTGCTCCA TCTTCTTATGCCCAAACCTCTG 
Slc2a2 CTCTTCCAACGTGGTCCCTA GAGCCCCTCGTAGGTTTTTC 
Kcnj11 TTGGAAGGCGTGGTACAAAC CCCCATAGAATCTCGTCAGC 
Gck ATAAGCCAGTGGTGGAGTGG CCAACACAGGTGTGAAGTGG 
Gapdh GTGGAGTCATACTGGAACATGTAG AATGGTGAAGGTCGGTGTG 
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Chapter 3 Investigation the Effect of Ad-PNM on Rat Pancreatic Exocrine Cell Line 
AR42J-B13 
 
3.1. Introduction 
PDX1 is a major pancreatic transcription factor. It belongs to the ParaHox gene 
family. Expression of Pdx1 is necessary both for formation of the pancreatic buds in the 
embryo and subsequently for beta cell formation and function (Jonsson, Carlsson et al. 
1994; Guz, Montminy et al. 1995). NGN3 is a member of basic helix-loop-helix 
transcription factor family. Expression of Ngn3 is essential for the formation of endocrine 
progenitor cells in the trunk epithelium of developing pancreas (Gradwohl, Dierich et al. 
2000). MAFA is a member of the basic leucine zipper transcription factor family. 
Expression of MafA is essential for maturation of beta cells (Kataoka, Han et al. 2002). 
Expression of Pdx1 and MafA genes is not only indispensable during pancreas 
organogenesis but they also positively regulate the expression of Insulin genes in beta 
cells. 
In the study of Zhou et al, the authors transformed pancreatic exocrine cells into 
insulin expressing beta-like cells in vivo by overexpressing the ectopic Pdx1, Ngn3 and 
MafA genes. They also reported that these insulin-positive cells restored the blood 
glucose level in streptozotocin-treated immunodeficient diabetic mice (Zhou, Brown et 
al. 2008). However, it is difficult to investigate the molecular mechanisms of cell 
transformation in vivo. For that reason we felt it important to establish an in vitro model 
for the process which is more amenable to study. For this purpose we selected the 
AR42J-B13 cell line which was shown as described above to give an extreme response to 
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Ad-PNM by transforming more than 70% of the cells into an insulin-positive state. 
AR42J-B13 is a rat cell line, which was originally derived from a chemically induced 
pancreatic tumor (Longnecker, Lilja et al. 1979), with a pancreatic exocrine phenotype. 
The cells are easy to grow in tissue culture and they express high levels of typical 
exocrine cell products like amylase, trypsin and carboxypeptidase A1. Unlike primary 
cultures of exocrine pancreas cells, AR42J-B13 cells have a stable phenotype during in 
vitro culture for a long period. Although there are reports in the literature of insulin-
positive cells arising from this line following culture on Matrigel and treatment with 
various growth factors (Mashima, Shibata et al. 1996; Aldibbiat, Marriott et al. 2008), we 
have not used such conditions in this study and saw no spontaneous endocrine 
differentiation of the AR42J-B13 cells under the conditions used.  
In this study, we investigated the effect of Pdx1, Ngn3 and MafA combination on 
rat exocrine cell line AR42J-B13 in a more detailed way to see the changes in their gene 
and protein expression profiles. Moreover we asked if the cells can gain glucose- 
controlled insulin releasing mechanism and restore blood glucose levels in 
streptozotocin-treated immunodeficient diabetic mice.  
 
3.2. Experimental Design and Methods 
 
3.2.1. Reverse Transcription–Polymerase Chain Reaction (RT-PCR) 
AR42J-B13 cells were cultured and transduced with Ad-PNM as described in 
Chapter B1. Total RNA isolation, DNase treatment and cDNA synthesis from AR42J-
B13 cells were performed as described in Chapter B1. The gene expression pattern 
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between AR42J-B13 cells with and without Ad-PNM was then compared by performing 
PCR for rat Ins1, Ins2, Gcg, Ppy, Sst, Iapp, Pax4, Neurod1, Nkx2.2, Arx, Pdx1, Ngn3, 
MafA, Nkx6.1, Isl1 , Mnx1, Pax6, Hes1, Slc2a2, Kcnj11, Abcc8, Cpe, Pcsk2, Amy2 (24 
cycles), Prss1 (Trypsin), Cpa1 (27 cycles), Ctrb1 (Chymotrypsinogen B1; 25 cycles), 
Rbpjl (Recombination signal binding protein for immunoglobulin kappa J region-like; 26 
cycles), Ptf1a and Actb (Beta actin), in addition to mouse Pdx1, Ngn3 and MafA. Rat 
whole pancreas cDNA was used as a positive control for Gcg, Sst and Ppy. cDNA from 
Ad-PNM-transduced HEK (human embryonic kidney)-293 cells was used as positive 
control for the input genes mouse Pdx1, Ngn3 and MafA. cDNA from RIN-m5F cells was 
used as positive control for the rest of the genes. After an initial denaturation at 94◦C for 
3 min, the reaction mixtures were subjected to 30 cycles (unless otherwise indicated) of 
amplification using the following conditions: 94◦C 30 s denaturation, 60◦C 30 s 
annealing, 72◦C 1 min extension. This was followed by a final extension step at 72◦C for 
5 min. Primer pairs used for RT-PCR are listed in Table 1. PCR products were then run 
on 1% (w/v) agarose gel (Invitrogen) including ethidium bromide, in TAE buffer (Bio-
Rad Laboratories), by electrophoresis at 100V. Agarose gels were visualized with a Bio-
Rad Gel Documentation System model 2000.  
 
3.2.2. Quantitative Reverse Transcription-Polymerase Chain Reaction (qRT-PCR) 
After transduction with Ad-PNM, AR42J-B13 cells were maintained in low-
glucose DMEM medium supplemented with 200μM of the anti-mitotic agent araC 
(cytosine arabinofuranoside; Sigma) to suppress the continued proliferation of non-
transformed AR42J-B13 cells. Total RNAs were isolated at different time points (0-12 
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days post-infection) using the RNeasy Mini Kit (Qiagen) according to the manufacturer's 
manual. DNase treatment and cDNA synthesis from these cells were performed as 
described in Chapter B1. The gene expression pattern between AR42J-B13 cells with and 
without Ad-PNM was then compared by performing qRT-PCR for rat Ins1, Ins2, Iapp, 
Pax4, Neurod1, Nkx2.2, Arx, endogenous Pdx1, endogenous Ngn3, endogenous MafA, 
Isl1, Mnx1, Hes1, Slc2a2, Kcnj11, Abcc8, Amy2, Ptf1a, Cpe, Pcsk2, Pcsk1, Prss1, Cpa, 
Ctrb1, Rbpj1 and Gapdh. After an initial denaturation at 95◦C for 30 s, reaction mixtures 
were subjected to 40 cycles of amplification using the following conditions: 95◦C for 5 s 
denaturation, and 60◦C for 10 s annealing and extension. The primer pairs used for the 
qRT-PCR are listed in Table 3. 
 
3.2.3. Immunostaining 
Immunostaining experiments were performed at different time points (0-12 days 
post-infection) as described in Chapter B1. Number of insulin-positive cells was also 
counted out of Ad-PNM bearing cells at different time points to see if there is any change 
in number of insulin-positive cells over time.  
 
3.2.4. EdU (5`-ethynl-2`-deoxyuridine) Labeling and Staining 
5×105 AR42J-B13 cells were used in EdU (5`-ethynl-2`-deoxyuridine) labeling 
experiments. EdU (10μM) from the Click-iT EdU 594 Imaging Kit (Invitrogen) was used 
for labeling. After the incubation (overnight and/or 1 hr), cells were fixed and stained for 
EdU, according to the manufacturer’s instructions to detect the number of cells in cycle 
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during the EdU treatment. Images were taken using a Leica DMI6000 B inverted 
microscope. 
 
3.2.5. ELISA for Total Insulin Content and Glucose-Stimulated Insulin Release 
AR42J-B13 cells (5×105) were plated in each well of a six-well plate. For control 
groups, cells in three wells were cultured without transduction. For experimental group, 
cells in the remaining three wells were transduced with Ad-PNM for overnight. After 
overnight incubation medium was changed and virus was removed. At 3 days after Ad-
PNM administration, DMEM medium was removed and cells were incubated either with 
2.8mM (low glucose environment) or 20mM (high glucose environment) glucose in KRB 
for 1 h at 37◦C. In some experiments 30mM KCl was included to effect depolarization of 
the cells. The KRB was then removed and kept at −20◦C for measurement of insulin 
release into the medium. After the removal of KRB, the cells were scraped into 0.18 M 
HCl/35% ethanol. The cells were homogenized by sonication with a Branson Sonifier 
450 (6×10 s on ice with 1 min waiting on ice between pulses) and were rotated overnight 
at 4◦C. The next day, the cells in acid/ethanol were subjected to centrifugation (10000 g 
for 30 min at 4◦C). The supernatant was collected and kept at −20◦C to measure the total 
amount of insulin in the cells. The remaining cell pellets after centrifugation were 
resuspended in 0.1M NaOH to measure the total amount of protein in the cells. The 
amount of the insulin released into the medium and the total insulin in the cells were 
measured using an Ultrasensitive Rat Insulin ELISA kit (Mercodia), according to the 
manufacturer’s instructions. The total protein amount in the cells was measured using the 
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BCA (bicinchoninic acid) protein assay kit (Thermo Scientific), according to 
manufacturer’s instructions. 
 
3.2.6. Mouse Experiments 
For the cell transplantation experiments, adult male NOD-SCID mice weighing 
22–27g (up to 42 days old) were injected intraperitoneally with streptozotocin (Sigma) at 
a dose of 120 mg/kg of body mass. The mice were considered diabetic when their blood 
glucose level reached a stable value over 400 mg/dl. The diabetic mice were then 
transplanted with Ad-PNM-transduced AR42J-B13 cells or with Ad-GFP-transduced 
AR42J-B13 cells as control. An aliquot of 2×106 cells were transplanted under the kidney 
membrane of each mouse. Blood was drawn from the tail vein and blood glucose levels 
were measured with a glucose meter every two days after the transplantation to see the 
change in the blood glucose level. At 10 days after cell transplantation, the kidneys with 
transplanted cells were removed and blood glucose levels of mice were monitored for 
two more days. The blood glucose changes were quantified by measuring the area under 
the curve, and comparisons were made using a Student’s t test. The excised kidneys were 
fixed in 10% (v/v) formalin (Fisher) and were processed for tissue sectioning. After 
antigen retrieval, tissue sections were immunostained for insulin, E-cadherin and DAPI 
(4`,6-diamidino-2-phenylindole) as described above. The mouse anti-E-cadherin (1:500 
dilution, BD Bioscience Pharmingen) primary antibody and Alexa Fluor® 488 goat anti-
mouse IgG (1:500 dilution, Invitrogen) secondary antibody were used to stain E-cadherin 
protein. 
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For expression of exogenous Pdx1, Ngn3 and MafA in the exocrine pancreas, 
adult CD1 mice were anaesthetized with avertin. A portion of skin was shaved and wiped 
with betadine. A small incision was then made and the pancreas everted from the wound. 
Ad-GFP or Ad-PNM (100μl; 1011 plaque-forming units/ml) were injected into the splenic 
lobe of the pancreas using an insulin needle. This caused formation of a visible bubble of 
fluid within the pancreas. The pancreas was reinternalized and the wound repaired in 
layers. The mice were killed 7 days later. The pancreases were removed, fixed in 10% 
(v/v) formalin (Fisher) and processed for tissue sectioning (frozen for GFP and paraffin 
for immunostaining). The tissue sections were stained for insulin and Ngn3 as described 
above. The animal experiments were carried out under IACUC (Institutional Animal Care 
and Use Committee) protocol 1007A85640 of the University of Minnesota. 
 
3.3. Results 
 
3.3.1. Effects of Pdx1, Ngn3 and MafA on AR42J-B13 Cells 
Administration of different adenoviral doses from 1 to 100 MOI indicated that for 
AR42J-B13 cells the optimum MOI was 25 and this dose was used in the experiments to 
be described. 
One day after Ad-PNM administration, cells changed their shape immediately 
from an oval structure to a more flattened fibroblast-like shape (Figure 11A and 11B). In 
the control group, in which cells were transduced with an adenovirus encoding GFP 
protein (Ad-GFP), cells did not have this phenotype (Figure11C) which showed that the 
change in cell shape was not a consequence of adenovirus infection itself. 
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In addition to cell shape, Ad-PNM also altered the gene expression pattern. RT-
PCR results are shown at 3 days after Ad-PNM administration (Figure 12) and qRT-PCR 
over a time course of 12 days (Figure 13). AraC, which kills dividing cells, was added 
into the cell culture medium for the 12 day studies to remove untransduced cells that 
continue to divide and would otherwise overgrow the cultures. qRT-PCR results therefore 
reflected just the Ad-PNM-transduced cells. After transduction with Ad-PNM, AR42J-
B13 cells started to express Ins1 and Ins2 genes. Iapp and Pax4 genes, which are not 
normally expressed in AR42J-B13 cells, were also activated. Moreover, expression level 
of genes encoding the beta cell transcription factors such as NEUROD1, NKX2.2 and the 
pro-insulin processing enzymes CPE and PCSK2, which were all expressed to some 
extent in the untreated cells, were increased in Ad-PNM treated AR42J-B13 cells. Abcc8, 
one of the genes for the ATP-sensitive potassium channel, was up-regulated, but Kcnj11, 
the gene for another component of this channel, was not. While a majority of the beta cell 
markers were up-regulated, the expression of all the exocrine acinar cell markers (Amy2, 
Prss1, Cpa1, Ctrb1, Rbpj1 and Ptf1a) was down-regulated, as was the centroacinar 
marker Hes1 in Ad-PNM-treated cells. There was approximately 100-fold fall in Amy2, 
Prss1 and Cpa1 transcripts, whereas the fall was approximately 10-fold in Ctrb1, Rbpj1 
and Ptf1a. Moreover, the genes encoding the hormones produced by the non-beta 
endocrine cell types found in the pancreas such as Gcg, Ppy, Sst and Ghrl (ghrelin) were 
not up-regulated. 
Based on RT- and qRT-PCR results, the Ad-PNM-treated AR42J-B13 cells 
transformed their phenotype into something more resembling that of pancreatic beta cells 
than that of pancreatic exocrine cells. On the other hand, the indispensable genes for a 
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beta cell phenotype, such as membrane channel proteins encoding Slc2a2 and Kcnj11, 
were not significantly up-regulated (Figures 12 and 13). One of the unique characters of 
beta cells is to secrete insulin in response to a rise in blood glucose concentration. The 
essential components of this mechanism are not all induced in our cells. These results 
indicate that the reprogramming of AR42J-B13 cells into pancreatic beta cells is 
incomplete. In addition, even though the reduction of exocrine cell gene expression, is 
striking, it is not complete. Moreover, expression is not induced from the endogenous 
counterparts of the three input genes. When designing the Ad-PNM, only the coding 
regions of Pdx1, Ngn3 and MafA were cloned into the vector. In other words, there was 
no 5` or 3` untranslated region (UTR) of input genes so that their mRNA could be 
distinguished from those of endogenous Pdx1, Ngn3 and MafA using suitable primers in 
PCR. Although the expression of Ngn3 might be expected to be confined to the period of 
formation of endocrine precursors, we would have expected to see Pdx1 and MafA 
expressed long-term in genuine beta cells, and it was not. 
We also showed the existence of insulin protein, its side product C-peptide, the 
major exocrine protein amylase, and the three input proteins PDX1, NGN3 and MAFA 
by immunostaining. Immunostained insulin protein was first observed at day 3 in the 
majority of Ad-PNM-transduced cells (Figure 14). These insulin-positive cells could 
persist in cell culture for at least 4 weeks (results are not shown). Some of the cells did 
not become insulin positive even though they are transduced with Ad-PNM (especially 
highly Pdx1, Ngn3, MafA positive cells were not insulin positive) but approximately 
70% of Ad-PNM bearing cells did so and this proportion remained similar over at least 
12 days (Figure 14D). The cells were shown to have C-peptide which was co-localized 
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with insulin. C-peptide is normally excised during the maturation of pro-insulin to the 
mature two chain structure and its presence in insulin-positive cells indicates that the pro-
insulin protein is properly processed after expression (Figure 14E). In addition, the 
presence of C-peptide also indicated that immunostained insulin was produced by cells 
instead of taken from the culture medium by dead and/or dying cells. Moreover, co-
immunostaining for amylase and insulin proteins showed that the insulin positive cells 
completely lost amylase protein which is one of the major products of pancreatic 
exocrine cells (Figure 14F). In these immunostaining experiments araC was not used so 
there were still untransduced AR42J-B13 cells present which were growing rapidly. This 
provides the internal positive control for amylase staining in Figure 14F. 
Another change we observed was that Ad-PNM transduced cells were slowing 
and/or stopping their cell cycle whereas untransduced cells kept proliferating rapidly. To 
verify this observation we looked at the proliferation ability of AR42J-B13 cells before 
and after Ad-PNM transduction by EdU administration and staining (Figure 15). A 4 h 
pulse of EdU labeled approximately 47% of the untreated AR42J-B13 cells as expected 
for a rapidly dividing population (Figures 15A and 15D). When we added Ad-PNM after 
such a 4 h pulse and examined the insulin-positive cells 3 days after Ad-PNM 
administration, a high proportion of the cells were labeled (~27%), although somewhat 
less than 47%, indicating that the transformation may occur either in or out of S-phase 
(Figures 15B and 15D). In other words, the stage of the cell cycle was not important for 
the cells to turn into an insulin-positive cell. However, if the cells were transduced with 
Ad-PNM first, left for 3 days and then were given an overnight label with EdU, the 
proportion of insulin-positive cells that were also EdU-labeled was extremely small 
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(~1%) (Figure 15C and 15D). This showed that cell division ceases almost entirely 
following the transformation. When we suppress the overgrowth by the untransformed 
AR42J-B13 cells by using araC, the fibroblast-shaped insulin-positive cells persisted for 
an extended period. We have maintained Ad-PNM-transduced cells in cultures with araC 
for 4 weeks, although there is some cell death of the insulin-positive cells over this 
period. 
 
3.3.2. Insulin Content and Secretion in Transformed Cells 
To quantify and compare the amount of the insulin produced, we measured total 
levels cells as well as secreted insulin in the medium by ELISA in AR42J-B13 cells with 
or without Ad-PNM. ELISA results showed a substantial insulin increase in Ad-PNM-
transduced cells (Figure 16A). However, the insulin level in Ad-PNM transduced cells 
did not reach the insulin level of mature beta cells which can contain as much as 5% of 
insulin as a proportion of total cell protein. Since glucose-stimulated insulin release is the 
key physiological property of genuine beta cells we examined this property by treating 
the cells with 2.8mM (low) or 20mM (high) glucose in KRB for 1 h and then analyzing 
the released insulin content of the medium by ELISA (Figure 16B). In addition to low 
and high glucose environment, we also tested the effect of KCl which produces complete 
depolarization of beta cells and causes them to emit a maximal amount of insulin. 
Untreated AR42J-B13 cells did not secrete any insulin as expected. The Ad-PNM-
transduced cells, on the other hand did secrete insulin, but in a completely unregulated 
manner, showing no effect of glucose or KCl. Based on these results, we concluded that 
the transformed cells did secrete insulin in a constitutive, but unregulated, manner. 
  78 
 
3.3.3. Insulin-Expressing AR42J-B13 Cells Rescue Diabetic Mice 
Insulin-expressing cell transplantation to ameliorate diabetes in experimental 
animals is one of the standard assays for a beta cell phenotype in diabetes studies. To 
fulfill this assay, we transplanted insulin-expressing AR42J-B13 cells to an immune-
deficient (NOD-SCID) mice line which will tolerate a graft of rat cells. Despite their 
name (non-obese diabetic), these mice are not diabetic, and diabetes is induced by an 
injection of the toxin streptozotocin, a chemical which preferentially destroys beta cells 
in pancreas to generate a model of Type 1 diabetes. 
Once the animals become diabetic (blood glucose level>400mg/dl), we 
transplanted Ad-PNM- transduced insulin-positive AR42J-B13 cells under the kidney 
capsule (only one kidney per animal was grafted) and then monitored the mice every two 
days. The fall in blood glucose indicates a relief of the diabetes. Following this, we 
removed the grafted kidneys for analysis. The rise of blood glucose after removal of the 
grafted kidney indicated that the relief of diabetes was in fact due to the graft and not to a 
non-specific effect of surgery or to consequent effects on feeding behaviour. Because of 
the risk of tumor formation from residual non-transformed AR42J-B13 cells, these 
experiments were terminated at 20 days after cell transplantation. Three out of ten mice 
were successfully engrafted with Ad-PNM-treated cells (■) (Figure 17A). 
Immunostaining of kidney sections from the excised kidneys demonstrated the persistent 
presence of insulin-positive rat cells under the kidney capsule (Figure 17B). The controls 
consisted of one mouse receiving Ad-GFP-treated cells (∆) and three receiving Ad-PNM-
treated cells, in which the graft did not take (●). The results were quantified by measuring 
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the area under the curve for each mouse from days 9–17 inclusive. This gave mean values 
of 1285 (S.D.=426) for the active grafts, 2531 (S.D.=385) for the grafts that did not take, 
and 2780 for the diabetic control. Comparison of the active grafts with those that did not 
take showed a P value of 0.020. Comparison of the active grafts with diabetic control 
gave a P value of 0.026. By contrast, comparison of the grafts that did not take with the 
diabetic control showed no difference (P=0.379). This result indicates that the Ad-PNM-
treated AR42J-B13 cells are capable of relieving diabetes in an animal model, even 
though they do not exhibit glucose-sensitive insulin secretion. 
 
3.3.4. Transduction of Exocrine Pancreas in vivo 
In addition to transformation we have seen in pancreatic exocrine cell lines in 
vitro, we wanted to see if Ad-PNM can transform pancreatic exocrine cells in vivo (Zhou, 
Brown et al. 2008). For this purpose, Ad-GFP or Ad-PNM were injected directly into the 
mouse pancreas as described previously (Zhou, Brown et al. 2008) and the results are 
shown in Figure 18. Injection of Ad-GFP showed a very high efficiency of transduction 
in exocrine tissue, with most cells expressing GFP protein. A small number of beta cells 
in the islets, visualized by immunostaining for insulin, were also transduced with Ad-
GFP (Figure 18A). When we gave a similar dose of Ad-PNM, once again a high level of 
transduction was detected by expression of the vector-encoded proteins. Figure 18B 
shows the expression of Ngn3, which is not normally found in mature exocrine or 
endocrine cells. The sections were stained for insulin and it was evident that a proportion 
of the scattered cells expressing NGN3 were also expressing insulin. The insulin 
expression was not necessarily observed in those cells expressing the highest levels of 
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NGN3, rather it was more likely to be observed in those with intermediate levels. This 
experiment confirms that the basic observation of Zhou et al. (Zhou, Brown et al. 2008) 
was correct. On the other hand it was difficult to establish for certain the phenotype of 
scattered cells in vivo. Consistent with the study of the AR42J-B13 cells, the insulin-
positive cells in vivo superficially resembled exocrine cells making insulin, rather than 
true beta cells. 
 
3.4. Discussion  
Generation of a particular adult cell type by direct reprogramming from another 
terminally differentiated adult cell type is of interest for many reasons. First of all, direct 
reprogramming studies have an important intellectual issue because it raises the question 
of whether the 200 or so visible cell types are the only possible stable states of vertebrate 
cells or whether numerous other states are potentially stable but are not accessed during 
normal development. This question can be experimentally probed by experiments in 
which developmental transcription factors are misexpressed in order to drive cells into a 
new developmental state. Because of the dense web of regulatory connections between 
developmental transcription factors, overexpression of a small number of factors can 
sometimes push the cell into a new state which involves a change in activity of thousands 
of genes. In case of medical practice, direct cell reprogramming can potentially solve 
many current problems such as shortage of a cell population to be transplanted, usage of 
immunosuppression therapy in cell transplanted-patients, or bypassing the need for ES 
cells to create a particular adult cell type. In the case of generation of the beta cell 
phenotype, direct reprogramming is also important from a practical point of view. 
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Following the publication by Zhou et al. (Zhou, Brown et al. 2008) we were 
motivated to perform the present study. In that study, formation of insulin-positive cells 
in the exocrine pancreas of mice after direct injection of three different adenoviruses 
encoding the three genes Pdx1, Ngn3 and MafA was shown by Zhou et al. Our results 
(Figure 18) indicated that the procedure can certainly induce ectopic insulin-positive 
cells, but it is not easy to prove that they are genuine beta cells with the full range of 
properties expected of this cell type. In order to facilitate mechanistic studies we carried 
out our experiments in in vitro by using a well known pancreatic exocrine cell line 
AR42J-B13. Our results showed that there is a remarkable phenotypic change in these 
cells after the ectopic expression the three genes. The cells change morphology to a flat 
fibroblast-like shape, stop dividing, down-regulate the expression of a range of exocrine 
markers, express insulin from both the endogenous genes and display a number of 
characteristic transcription factors normally found in beta cells. However, the 
reprogramming is not complete, since the endogenous counterparts of the introduced 
genes were not up-regulated, and some components of the all-important glucose-sensing 
mechanism of beta cells were not induced. We showed this both from the lack of 
expression of the Slc2a2 and Kcnj11 genes and from the lack of glucose-induced insulin 
secretion by these cells. In a previous study (Aldibbiat, Marriott et al. 2008), which 
involved formation of insulin-positive cells from AR42J-B13 cells cultured on Matrigel 
and treated with growth factors, it was also reported that insulin secretion from these cells 
was not glucose-regulated. On the other hand, recently Lima et al. showed that ectopic 
expression of Pax4 together with Pdx1, Ngn3 and MafA can stimulate glucose-controlled 
insulin secretion in AR42J-B13 cells (Lima, Docherty et al. 2012). Even though 
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endogenous Pax4 was activated significantly in our cells after transduction with Ad-
PNM, we still did not observe glucose-regulated insulin secretion in the current study. 
If cellular reprogramming to beta cells does eventually become a method for 
clinical use, it is likely to take the form of in vitro cell transformation followed by a graft 
similar to the current islet transplantation procedure. This is because direct introduction 
of genes into the pancreas is likely to pose risks of oncogenic transformations as seen in 
other types of gene therapy (Flotte 2007). Thus it is necessary to show that the 
transformed cells can indeed cure diabetes following transformation. In our case we have 
shown that the Ad-PNM-treated AR42J-B13 cells can cure streptozotocin induced 
diabetes. However, we have good evidence that the cells are not glucose-responsive, so 
their curative ability must derive from their constitutive insulin secretion. This is a 
reminder that the ability to rescue experimental diabetes in rodents is not a very 
discriminating characteristic. For treatment of human diabetes, cells must have the exact 
glucose responsiveness of real beta cells or they will not be significantly better than the 
present regimes of insulin injection. Whether beta cells are obtained by direct 
reprogramming or from other sources, such as directed differentiation of pluripotent stem 
cells (Murry and Keller 2008), it will be necessary to carefully characterize the phenotype 
of the cells before proceeding. 
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Figure 11: Effect of Ad-PNM on cell shape 
Shape of the AR42J-B13 cells changed from an oval structure to a more flattened 
fibroblast-like shape after Ad-PNM transduction. AR42J-B13 cells (A) with no treatment, 
(B) with Ad-PNM, (C) with Ad-GFP. Scale bars =100μm.  
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Figure 12: Gene expression profile of AR42J-B13 cells after Ad-PNM (RT-PCR) 
AR42J-B13 cells were transduced with Ad-PNM. 3 days after Ad-PNM transduction 
gene expression profile between Ad-PNM transduced and nontransduced cells were 
compared through RT-PCR.  
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Figure 13: Gene expression profile of AR42J-B13 cells after Ad-PNM (qRT-PCR) 
AR42J-B13 cells were transduced with Ad-PNM. Gene expression profile between Ad-
PNM transduced and nontransduced cells were compared through qRT-PCR at different 
time points (i.e 0, 3, 6, 9 and 12 days after Ad-PNM). Top panel is showing the 
expression pattern of endocrine cell markers. Bottom panel is showing the expression 
pattern of exocrine cell markers.  
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Figure 14: Expression of insulin and exogenous Pdx1, Ngn3 and MafA in AR42JB13 
cells 
AR42J-B13 cells were fixed and immunostained 3, 6, 9, 12 days after Ad-PNM 
transduction for (A) insulin (red) and Pdx1 (green), (B) insulin (red) and Ngn3 (green), 
(C) insulin (red) and MafA (green). (D) Percentage of insulin-positive cells out of the 
population of Ad-PNM bearing cells over time. Data are means ± S.E. (n =3). (E) C-
peptide (green), insulin (red) and DAPI (blue) at day 12. (F) Amylase (green), insulin 
(red) and DAPI (blue) at day 6. Scale bars =100μm. 
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Figure 15: AR42J-B13 cell proliferation assay with EdU 
(A) AR42J-B13 cells were given EdU for 4 h. Then they were fixed and stained for EdU 
(red) and DAPI (blue). (B) AR42J-B13 cells were given EduU for 4 h. Then the cells 
were transduced with Ad-PNM. 3 days after, cells were fixed and stained for EdU (red), 
insulin (green) and DAPI (blue). (C). AR42J-B13 cells were transduced with Ad-PNM. 
At 3 days these cells were given EdU overnight. Next day they were fixed and stained for 
EdU (red), insulin (green) and DAPI (blue). Scale bars =100μm. The red colour is 
slightly enhanced in (B and C) to be consistent with (A). (D) Left-hand bar: percentage of 
proliferating cells out of total population. Middle and right-hand bars: percentage of 
proliferating insulin-positive cells out of total insulin-positive cells. Data are means ± 
S.E. (n =3). 
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Figure 16: Total and secreted insulin amount of AR42J-B13 cells by ELISA 
(A) The total insulin amount in the AR42J-B13 cells with and without Ad-PNM was 
measured by ELISA. (B) The amount of insulin in the medium released from AR42J-B13 
cells with and without Ad–PNM was measured by ELISA. Cells were stimulated either 
with low-glucose (open bars) or high-glucose (closed bars) and KCl. Experiments with 
Ad-PNM-treated cells were performed 3 days after transduction. Data are means ± S.E. 
(n =3). 
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Figure 17: Amelioration of diabetes by Ad-PNM-transduced AR42J-B13 cells 
(A) Mice were given STZ to induce diabetes at day 0. Cells were transplanted under the 
kidney capsule at day 7 (grey arrow). Blood glucose levels were then measured every 2 
days. At day 17 the transplanted kidneys were removed and analyzed for the presence of 
graft cells (black arrow). ∆, Ad-GFP-treated cells (control); ■, Ad-PNM-treated cells, n 
=3 and one mouse died after kidney removal; ●, Ad-PNM-treated but without successful 
engraftment, n =3. Results are means ± S.E. (B) Explanted kidneys were stained for 
insulin (red), E-cadherin (green) and DAPI (blue). Scale bar =100μm.
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Figure 18: Transduction of the exocrine pancreas in vivo 
(A) Injection of pancreas with Ad-GFP, visualized by GFP fluorescence, showing a high 
level of transduction in exocrine tissue. (B) Transduction with Ad-PNM, immunostained 
for Ngn3 (green) and insulin (red). Scale bars =100μm. 
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Table 3: Rat primers used in qRT-PCR
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Rat Primers used in qRT-PCR 
Primer 
Name Forward Sequence 5`-3` Reverse Sequence 5`-3` 
Ins1 CAATCATAGACCATCAGCAAGC AGAAACCACGTTCCCCAC 
Ins2 CCCAGGCTTTTGTCAAACAG GTGCCAAGGTCTGAAGGTC 
Iapp CCACTGAAAGGGATCTTGAGAC TTCCGTTTGTCCACCTGAG 
Pax4 GGGCAGTATCCAGATTCAGTTG GGCATCTGTGTTTCCCATTTC 
Neurod1 ATGTCTTCCACGTCAAGCC GAGAAGTTGCCATTGATGCTG 
Nkx2.2  GGTCAAGATCTGGTTCCAAAAC GTCACCTCCATACCTTTCTCAG 
Arx  AATCTAACCCATCCCCAACAC CTCTTCCTGGTACTGATTGCTC 
Endogenous 
Pdx1 
CCCGAGCTTCTGAAAACTTTG CTTTTCATTGTCCTCAGTTGGG 
Endogenous 
Ngn3 
TCCAGACGCAATTTACTCCAG CTAGTTCTCCGGGCTCAAAAG 
Endogenous 
MafA 
TCTTTCTGTGAGCGCGG TCAGAGTCCGAACCGAGG 
Isl1 TTGTTAGGGACGGGAAAACC CTACACAGCGGAAACATTCG 
Mnx1 GCTTTCCTACTCGTATCCTCAG TTCCCCAAGAGGTTCGATTG 
Hes1 AGAAAAATTCCTCGTCCCCG TTTCATTTATTCTTGCCCGGC 
Slc2a2 CACATCCTACTTGGCCTATCTG TCAGTGCCCCTTAGTCTTTTC 
Kcnj11 TCAGTAAGCAATGAGCAGGG CAACCTCTGGACTGATATGCC 
Abcc8 AGAAGCTCCTAGAGTACACCG TGTAGGGAGTTGGAGATGGAG 
Amy2 GCAGACCTTTCATTTTCCAAGAG ACAAAACCCCAACCTTCTCC 
Ptf1a AGGACCCCAGAAAACTCAAC CAATATGCACAAAGACACAGCC 
Cpe  ATGGTAATGAGGCGGTTGG AGGGCATGATATGGATTCGTG 
Pcsk1 CTCAGCCCTTCCTACTTGTG CATTGACAAACTGCCTCTTCG 
Pcsk2 GCATAAAGACGGAGAGGAAGAG TGGTAAAAGTGGTACAGGCC 
Prss1 GTGTATCCTCCAACGATCTTGT CACTTCTGATCCTAGCCCTTG 
Cpa1 CCAGAAGTCCAACTGCAAGT CAGTCTGTGGCAATGAGAACT 
Cpb1 CACGTTGCTTATCAGTACCTCA GCCTCTCACTACAGTTGACTT 
Ctrb1 GAATAGCATCCTCTCCGTTGAC GTCCTGCTTTGCCCTTGT 
Rbpjl CATCTCCGAACCACACCTTG CTCCAGTGCCTCATATCAGC 
Gapdh TCCAGTATGACTCTACCCACG CACGACATACTCAGCACCAG 
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Chapter 4 Comparision of Epigenetic Patterns of Developmentally Related Cells 
and Effect of Ad-PNM on Epigenetic Modifications 
 
4.1. Introduction 
During formation of a specific cell lineage, configuration of active genes 
encoding specific differentiation products is important. After formation of a cell lineage 
configuration of regulatory genes that maintain the state in a stable manner is important 
as well. For both it is clear that an essential feature of the differentiated cell state is the 
chromatin state of key genes. Two types of epigenetic modification; histone tail 
modifications and DNA methylation have been shown to be important in this context. 
Acetylation of the lysine residues on the histone tails is one of the modifications 
which regulates the expression of genes, generally in favor of gene activation (Hebbes, 
Thorne et al. 1988). This reaction is catalyzed by histone acetyltransferase (HAT) 
enzymes by which acetyl groups are transferred from acetyl-coenzyme A to lysine 
residues. Acetylation of the lysine residues removes the positive charge of the epsilon 
amino groups which reduces the interaction between histone tails and the negatively 
charged phosphate groups of DNA, thus relaxing the chromatin structure at the acetylated 
regions. In the relaxed chromatin area, transcription factors and the general transcription 
machinery members can easily reach their target genes and can initiate transcription. On 
the other hand, deacetylation of the lysine residues by histone deacetylase (HDAC) 
enzymes reverses this effect, condensing the chromatin structure in the deacetylated 
regions. A condensed chromatin area is not easily accessible by transcription factors or 
the general transcription machinery so that genes in that area are not transcribed. 
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Methylation of lysine and arginine residues of the histones tails is another histone 
tail modification regulating gene expression (Chen, Ma et al. 1999). This reaction is 
catalyzed either by lysine specific (SET domain containing or non-SET domain 
containing) or arginine specific histone methyltransferase (HMT) enzymes by which S-
adenosyl methionine is used as methyl donor. While methylation of lysine 4 on H3 
(H3K4) and the arginine residues on H3 (H3R) as well as H4 (H4R) can stimulate active 
gene expression, dimethylation of lysine 9 on H3 (H3K9Me2) and trimethylation of 
lysine 27 on H3 (H3K27Me3) are signatures of transcriptional repression (Jenuwein and 
Allis 2001).  
In addition to histone tail modifications, DNA base methylation in CpG rich areas 
can also regulate gene expression. This reaction is catalyzed by DNA methyl transferase 
(DNMT) enzymes by which a methyl group is transferred from S-adenosyl methionine to 
5 position of the cytosine pyrimidine ring in CpG dinucleotide (Hergersberg 1991). 
Active genes are usually associated with a relative undermethylation of CpGs in their 
regulatory regions ("CpG islands") (Bird 2002). Repressed genes, on the other hand, are 
associated with a high level of methylation in their regulatory regions. Methylated DNA 
may repress the active transcription via two possible mechanisms: a) preventing the 
binding of the general transcription machinery physically as well as other transcription 
factors to methylated promoter regions; and b) Accumulation of specific transcriptional 
repressor proteins (methyl-CpG-binding domain proteins) which recognize the 
methylated CpGs (Kass, Pruss et al. 1997) and prevent the binding of the general 
transcription machinery as well as other transcription factors which favor gene 
transcription. 
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Acinar cells of exocrine pancreas are considered to be developmentally close to 
beta cells of endocrine pancreas since both exocrine and endocrine regions of the 
pancreas arise from the same endodermal cell population during pancreas development 
(Percival and Slack 1999; Gu, Dubauskaite et al. 2002). In other words, before endocrine 
and exocrine lineage commitment these cells are believed to share the same epigenetic 
pattern. The common impression is that different adult cells which are developmentally 
related can be  reprogrammed into each other by overexpression of selected transcription 
factors, typically ones that are involved in the normal embryonic development of the cell 
type in question like Pdx1, Ngn3 and MafA for beta cells (Gu, Dubauskaite et al. 2002; 
Zhou and Melton 2008) 
The notion of high reprogramming competency of developmentally related cell 
types into each other is supported by our previous results where we showed that primary 
rat hepatocytes and rat pancreatic exocrine cell line AR42J-B13 can activate not all but 
many beta cell genes after transduction with Ad-PNM. Compared to AR42J-B13 cells, 
primary rat hepatocytes activated more beta cell genes based on RT-PCR results (Figure 
5). However, by immunostaining the number of insulin positive cells after Ad-PNM 
transduction was higher in AR42J-B13 cells than rat primary hepatocytes (Figure 6). 
In this study we compared the epigenetic state (histone tail modifications and 
DNA methylation) of developmentally related (RIN-m5F and AR42J-B13) and unrelated 
(IRPT and AR42J-B13) cells for three important beta cell genes: Ins1, Ins2 and Pdx1. We 
also examined the epigenetic modifications of the same three genes for AR42J-B13 cells 
after transduction with Ad-PNM. 
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Some of the important cis-regulatory elements and CpGs at the proximal 
promoters and first exons of Ins1, Ins2 and Pdx1 genes are shown in Figure 19, 20 and 
21, respectively. Ins1 and Ins2 basal promoters include a TATA box (TATAA; ~25-30bp 
upstream from start of transcription) which binds transcription factor IID (TFIID) 
through TATA box binding protein (TBP). Binding of TFIID to TATA box will then 
recruit the other members of the general transcription machinery for active gene 
transcription (Patikoglou, Kim et al. 1999). CAAT box (CCAAT; ~75-80bp upstream 
from start of transcription), which normally binds CAAT binding protein (CBP) and 
CAAT/enhancer binding protein (C/EBP), is combined with a CRE box both in Ins1 and 
Ins2 genes of rodents. CRE/CAAT combined site was shown to bind nuclear 
transcription factor-Y (NF-Y) (Eggers, Siemann et al. 1998). However, neither 
CRE/CAAT combined box nor CAAT box alone are present in other mammals. This fact 
raises the idea that CAAT box may not have a role in Insulin gene expression (Hay and 
Docherty 2006). Homeodomain protein-binding, TAAT motif-including (except for A2) A 
boxes are present in Ins1 (A1, A2, A3 and A4) and Ins2 (A1, A2 and A3) proximal 
promoters of rat (Melloul, Marshak et al. 2002). A1 and A3 boxes are the most conserved 
and were shown to control Insulin genes expression by binding the PDX1 transcription 
factor (Melloul, Marshak et al. 2002). C1 box is another conserved regulatory element in 
Ins1 and Ins2 promoters and it was shown to control Insulin genes expression by binding 
MAFA transcription factor (Olbrot, Rud et al. 2002). E boxes (CANNTG), which binds 
basic-helix-loop- helix (bHLH) class of transcription factors, are also present in Ins1 (E1 
and E2 boxes) and Ins2 (E1 box) promoters of rat (Karlsson, Edlund et al. 1987). Unlike 
Ins1 and Ins2 promoters, Pdx1 promoter does not contain a TATA box. On the other 
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hand CAAT and E boxes are present at the proximal promoter of Pdx1 gene (Campbell 
and Macfarlane 2002).   
 
4.2. Experimental Design and Methods 
 
4.2.1. ChIP (Chromatin Immunoprecipitation) for Histone Tail Modifications and 
qPCR (Quantitative Polymerase Chain Reaction) 
AR42J-B13 cells (107) with no Ad-PNM, AR42J-B13 cells 3 days after 
administration of Ad-PNM, RIN-m5F cells or IRPT cells were plated on 20 cm tissue 
culture dishes. Formaldehyde (36.5%; Sigma) was added to the dishes to a final 
concentration of 1% in each dish and cells were incubated for 10 min at room 
temperature. The cross-linking reaction was quenched by addition of 2ml of 1.25M 
glycine (Sigma). The cells were then scraped into 50ml conical tubes and were subjected 
to centrifugation (10000 g for 15 min at 4◦C). The supernatant was discarded after 
centrifugation. Cell and nucleus lysis buffers (Magna ChIPTM G Kit, Millipore) were 
added to the remaining cell pellets. The cells/DNAs were sheared by sonication using a 
Branson Sonifier 450 (15×10 s on ice with 1 min waiting on ice between pulses). Then 
ChIP (chromatin immunoprecipitation) was performed for H3K4Me3 (trimethylated Lys4 
of histone 3), H3K9Me2 (dimethylated Lys9 of histone 3), H3K27Me3 (trimethylated 
Lys27 of histone 3) and H3Ac (acetylated histone 3) by using Magna ChIPTM G Kit 
(Millipore), according to the manufacturer’s instructions. Antibodies used for ChIP were: 
rabbit anti-H3K4Me3 mAb (monoclonal antibody; Cell Signaling Technology), mouse 
anti-H3K9Me2 mAb (Abcam), mouse anti-H3K27Me3 mAb (Abcam) and rabbit anti-
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H3Ac polyclonal antibody (Millipore). For each immunoprecipitation reaction 5μg of 
antibody was used. After immunoprecipitation of DNA fragments bearing the histone 
modifications mentioned above, qPCR was performed by using specific primer pairs 
(Table 4) which span approximately −200bp (base pair) to +50bp of the Ins1, Ins2 and 
Pdx1 genes. These regions include a number of important regulatory sites as shown in 
Figure 19, 20 and 21 (German, Ashcroft et al. 1995; Gannon, Gamer et al. 2001; 
Campbell and Macfarlane 2002; Iype, Francis et al. 2005; Miyatsuka, Matsuoka et al. 
2007). In qPCR, reaction mixtures were incubated at 50◦C for 2 min and then at 95◦C for 
10 min for initial denaturation. Reaction mixtures were then subjected to 40 cycles of 
amplification using the following conditions: 95◦C for 15 s denaturation, 60◦C for 30 s 
annealing and 60◦C for 30 s extension. An Eppendorf Realplex4 mastercycler was used 
for these qPCRs. To normalize the ChIP data, the fold enrichment method (also known as 
signal over background) was used in which ChIP signals were divided by non-specific 
antibody signals. 
 
4.2.2. DNA Methylation Assay with Bisulfite Sequencing 
Isolation of genomic DNA from AR42J-B13 cells with no Ad-PNM, from 
AR42J-B13 cells with 3 days after Ad-PNM, RIN-m5F cells or IRPT cells was 
performed with QIAamp DNA Mini Kit (Qiagen), according to the manufacturer’s 
instructions. Bisulfite conversion of isolated genomic DNA was performed with the EZ 
DNA methylation-gold kit (Zymo Research), according to the manufacturer’s 
instructions. Bisulfite-treated DNA-specific primer pairs (Table 3) which are spanning 
the proximal promoters and first exons of Ins1, Ins2 and Pdx1 genes were designed by 
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using MethPrimer software (Li and Dahiya 2002). To amplify the bisulfite-treated 
genomic DNA, a PCR was performed. In this PCR, samples were heated at 95 ◦C for 10 
min as initial denaturation. Reaction mixtures were then subjected to 40 cycles of 
amplification using the following conditions: 95◦C for 30 s denaturation, 50◦C for 40 s 
annealing, 72◦C for 1 min extension. This was followed by a final extension step at 72◦C 
for 7 min. Hot Taq DNA Polymerase (Zymo Research) was used in these PCR reactions. 
Amplified PCR products were then run on 1% (w/v) agarose gel in 1x TAE buffer by 
electrophoresis at 100 V. DNA fragments of interest were cut out from the gel and 
purified with Wizard SV Gel and PCR Clean-Up System (Promega), according to the 
manufacturer’s instructions. Purified PCR products were cloned into the pCR4-TOPO 
vector with TOPO TA Cloning Kit (Invitrogen) for subsequent sequencing. Plasmids 
including the DNA fragments of interest were transformed into the chemically competent 
One Shot TOP10 cells provided by the kit, according to the manufacturer’s instructions. 
Cells were grown on LB (Luria–Bertani) agar plates containing kanamycin. From each 
plate ten colonies were picked up randomly and grown in kanamaycin including LB broth 
overnight at 37◦C in a shaking incubator. The next day plasmid DNAs were isolated by 
using Wizard Plus SV Minipreps DNA Purification System (Promega), according to the 
manufacturer’s instructions. Each collected clone was restriction-digested with EcoRI 
(Promega) to verify that they contain the right DNA fragments of interest. Then ten 
different clones for each DNA fragment were sequenced by the DNA Sequencing and 
Analysis Facility, Biomedical Genomics Center, University of Minnesota, MN, U.S.A. 
 
4.3 Results 
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4.3.1. Effects on Histone Tail Modifications at Pdx1 and Insulin Genes 
Methylation and acetylation of histone tails are functionally important either for 
up-regulation or repression of a gene (Jenuwein and Allis 2001; Eberharter and Becker 
2002). Modifications such as H3K4Me3 and H3Ac for instance, are two of the indicators 
for active transcription when they are found in histones at the promoter region of a gene. 
Modifications such as H3K9Me2 and H3K27Me3 are two indicators of transcriptional 
repression. 
During a cell reprogramming event, regulatory genes controlling the cell 
phenotype as well as the genes encoding the differentiation products for the cell in 
question are expected to be activated. For this reason we examined four histone tail 
modifications (H3K4Me3, H3Ac, H3K9Me2 and H3K27Me3) at the promoter of the 
endogenous Pdx1, Ins1 and Ins2 genes (German, Ashcroft et al. 1995; Gannon, Gamer et 
al. 2001; Campbell and Macfarlane 2002; Iype, Francis et al. 2005; Miyatsuka, Matsuoka 
et al. 2007) (Figure 22). The housekeeping gene Gapdh (which is active in all cell types) 
was used as positive control (Figure 22A). We compared RIN-m5F cells (a rat 
insulinoma cell line which is Ins1+, Ins2+ and Pdx1+), AR42J-B13 cells without Ad-
PNM (which are Ins1−, Ins2− and Pdx1−), the AR42J-B13 cells with Ad-PNM (which 
are Ins1+, Ins2+ and Pdx1−) and IRPT cells (a rat kidney cell line which is Ins1−, Ins2− 
and Pdx1−). We first performed chromatin immunoprecipitation (ChIP) for H3K4Me3, 
H3K9Me2, H3K27Me3 and H3Ac modifications and then ran qRT–PCR for the promoter 
regions under study. For the Ad-PNM-transduced cells, ChIP was conducted 3 days after 
Ad-PNM transduction. 
  109 
At the Pdx1 promoter of the AR42J-B13 cells, Ad-PNM increased the proportion 
of H3K4Me3 to a modest extent and it did not change the level of H3K9Me2, H3K27Me3 
or H3Ac (Figure 22B). This result was consistent with the failure to activate endogenous 
Pdx1 gene as shown by the RT–PCR studies. At both the Ins1 and Ins2 promoters of 
AR42J-B13 cells, Ad-PNM reduced the inhibitory H3K9Me2 and H3K27Me3 proportions 
to a degree (not statistically significant for Ins2 H3K27Me3) (Figures 22C and 22D). This 
result was consistent with the up-regulation of Ins1 and Ins2 genes as shown by RT–PCR 
studies. Before the ChIP experiments, we had hypothesized that the chromatin for 
regulatory genes such as Pdx1 might be ‘open’ in pancreatic exocrine cells and ‘closed’ 
in non-pancreatic cells such as the kidney. As shown in Figure 22B this is the case in 
relation to the active expression indicator H3K4Me3 and the two inhibitory indicators 
H3K9Me2 and H3K27Me3. However since we see no significant up-regulation of 
endogenous Pdx1 with Ad- PNM it may be that the chromatin is not really accessible and 
is rendered inactive by other modifications not examined in the present study. 
 
4.3.2. Effects on Promoter Methylation at Pdx1 and Insulin Genes 
Together with histone tail modifications such as methylation and acetylation, the 
methylation of the DNA base cytosine at promoter regions of the genes is another 
important epigenetic factor affecting gene expression. The methylation of cytosines at 
CpG islands is usually associated with repression of gene activity (Bird 2002). To 
examine the effects of Ad-PNM on the DNA methylation pattern in treated cells, we 
compared the same four cell populations used for the ChIP analysis and performed 
bisulfite sequencing for the same promoter regions of Pdx1, Ins1 and Ins2 genes. Our 
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results showed that the expression of the Pdx1 gene is not under the control of DNA 
methylation at the sites examined, as there is no CpG methylation at either proximal 
promoter or exons in any of the cell types (Figure 23C). Unlike Pdx1, the expression of 
the Ins1 gene correlated with DNA methylation at the proximal promoter (Figure 23A). 
In RIN-m5F cells (which are Ins1+), the CpG methylation ratio was only 2% at the 
proximal promoter of Ins1 as compared with 63% for the whole gene. In IRPT cells 
(which are Ins1−), the CpG methylation ratio was 90% at the proximal promoter of Ins1 
compared with 47% for the whole gene. This result suggests that demethylation of the 
proximal promoter of the Ins1 gene was necessary for the gene expression. Like IRPT 
cells, the proximal promoter of the Ins1 gene of AR42J-B13 cells (which are Ins1−) is 
highly methylated at 90%. After transduction with Ad-PNM (such that the cells become 
Ins1+), CpG methylation at the proximal promoter was reduced to 28%, with little 
change of methylation in the Ins1 exon. Unlike Ins1, the expression of the Ins2 gene may 
not be under the control of DNA methylation at the sites examined as there was no 
correlation with expression state (Figure 23B). In the RIN-m5F cells (Ins2+), the 
methylation ratio was 88% at the proximal promoter of Ins2 and 89% throughout the 
whole gene. In IRPT cells (Ins2−), the methylation ratio was 42% at the proximal 
promoter of Ins2 and 40% throughout the whole gene. After transduction with Ad-PNM 
the methylation ratio in AR42J-B13 cells fell slightly from 40% to 35% at the proximal 
promoter of Ins2 and from 54% to 49% throughout the whole gene. 
In summary, our results from the DNA base methylation study indicated that there 
was no pre-existing competence of these genes for upregulation in the pancreatic cells as 
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compared with the kidney cells, and that of the genes examined Ins1 showed promoter 
demethylation following Ad-PNM treatment, whereas Ins2 does not.  
 
4.4. Discussion 
Both exocrine and endocrine cell types arise from the same endodermal cell 
population of the pancreatic bud during pancreas development (Percival and Slack 1999; 
Gu, Dubauskaite et al. 2002). As a result of their developmental relatedness, endocrine 
and exocrine cells might share some aspects of chromatin state, and this may facilitate 
interconversion by overexpression of selected transcription factors. For instance, in 
pancreatic exocrine cells perhaps the genes characteristic of pancreatic endocrine cells, 
while not being expressed, are still accessible to transcription factors rather than being 
sequestered in inactive regions of chromatin. For this reason we performed histone tail 
modification and DNA base methylation studies for Pdx1, Ins1 and Ins2 genes. In the 
case of Pdx1, which is a key regulatory gene in pancreatic development, the histone tail 
modification studies did suggest an open configuration in the pancreatic, but not the non-
pancreatic, cell types. Although our line of AR42J-B13 cells does not express Pdx1, other 
lines of the original cells in use elsewhere have been reported to do so in their normal 
state (Aldibbiat, Marriott et al. 2008; Ogihara, Fujitani et al. 2008). With regard to the 
Insulin genes, the results of the histone tail modification and DNA base methylation 
studies indicate that the introduction of the Pdx1, Ngn3 and MafA combination itself 
modifies the chromatin to promote expression. 
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Figure 19: Rat Ins1 gene 
Location of primer pairs used for ChIP, and CpGs sequenced for methylation analysis, in 
the genomic sequence of Ins1. Black = proximal promoter; Blue =5` UTR; Red =First 
exon. The sequences in brackets indicate known regulatory elements. Primers for ChIP-
qPCR are highlighted in yellow. CGs shown here in large type were sequenced in the 
DNA methylation assay. 
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Figure 20: Rat Ins2 gene 
Location of primer pairs used for ChIP, and CpGs sequenced for methylation analysis, in 
the genomic sequence of Ins2. Black = proximal promoter; Red =First exon. The 
sequences in brackets indicate known regulatory elements. Primers for ChIP-qPCR are 
highlighted in yellow. CGs shown here in large type were sequenced in the DNA 
methylation assay. 
  115 
  116 
Figure 21: Rat Pdx1 gene 
Location of primer pairs used for ChIP, and CpGs sequenced for methylation analysis, in 
the genomic sequence of Pdx1. Black = proximal promoter; Blue =5` UTR; Red =First 
exon. The sequences in brackets indicate known regulatory elements. Primers for ChIP-
qPCR are highlighted in yellow. CGs shown here in large type were sequenced in the 
DNA methylation assay. 
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Figure 22: Changes of the histone tail modifications at the promoter regions of the 
Pdx1, Ins1 and Ins2 genes after Ad-PNM 
ChIP assays were carried out to compare the proportion of the histone tail modifications 
(H3K4Me3, H3K9Me2, H3K27Me3 and H3Ac) at the promoters of the Gapdh (A), Pdx1 
(B), Ins1 (C) and Ins2 (D) genes. The cell types analyzed are RIN-m5F cells (stippled 
bars), AR42J-B13 cells without Ad-PNM (open bars), AR42J-B13 cells with Ad-PNM 
(closed bars) and IRPT cells (diagonal hatched bars). The y-axis shows fold change of 
samples over negative control rat IgG. Data are means ± S.E. (n =3). 
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Figure 23: Changes of the DNA methylation pattern of the Pdx1, Ins1 and Ins2 
genes after Ad-PNM 
Comparison of the CpG methylation pattern of the Ins1 (A), Ins2 (B) and Pdx1 (C) genes 
in RIN-m5F cells, AR42J-B13 cells with and without Ad-PNM, and IRPT cells. Each 
circle, divided into ten wedges, represents ten different clones for the same CpG. Open 
wedges represent unmethylated CpGs and closed wedges represent methylated CpGs. 
Intact open circles represent CpGs that were not covered by the bisulfite sequencing. 
UTR, untranslated region. 
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Table 4: Rat primers used in ChIP qPCR
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Rat Primers used in ChIP qPCR 
Primer 
Name Forward Sequence 5`-3` Reverse Sequence 5`-3` 
Ins1  CCAATGAGCGCTTTCTGCAGACTT AGGAGAGTACATACCTGCTTGCTG 
Ins2 ACCAGGCAAGTGTTTGGAAACTGC ATGTAAGAGAAGAGCCCACAGCGT 
Pdx1  AGAGATCAGCCTGCTGAGAGAGAA TACTGCTCCTCACTATTCATGGTGGC 
Gapdh CTTTACGGGTGCACGTAGCTCA TTTCACCTGGCACTGCACAAGAAG 
Rat Primers used in DNA methylation assay 
Ins1 
set1 
TTTTAGGTTTAAGTAGAGTTGTTGA CCCTAAAATTTTAACTAAAAAAACC 
Ins1 
set2 
GTTTTTTGTTTTTGTTGGTTTTGTT CACCCAACTCCAATTATAACACTTAC 
Ins1 
set3 
TTTTTGGGAGTTTAAGTTTGTTTAG ATACAACACTAATCCACAATACCAC 
Ins2 
set1 
TTTGAGTTTTTTATTTGTTTTTTTT CTAATTTAATACTACCCTATTCCCC 
Ins2 
set2 
GATTATAAAGTTAGTGGGGATTTAGTAAT TATTTAACAAAAACCTAAACAAAAC 
Ins2 
set3 
GTATTTTTGTGGTTTTTATTTGGTG ACTTACCTTATAAATCCTCCACTTC 
Pdx1 
set1 
AGGAGAGATTAGTTTGTTGAGAGAGAA AAAAACTACAAACCAAACCTTAAAC 
Pdx1 
set2 
ATTATGAATAGTGAGGAGTAGTATTA AAAAACTTCCCTATTCCAAC 
Pdx1 
set3 
GTTGGAATAGGGAAGTTTTT ACTTACCTACCCACTAACTTTTCCAC 
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Chapter 5 Effects of Small Molecules Together with Ad-PNM on Mouse 
Hepatocyte-Derived Small Cells 
 
5.1 Introduction 
The mouse hepatocyte-derived small cells, which are called ASH cells here, were 
derived from primary mouse hepatocytes maintained in tissue culture over a month by 
Dr. David Tosh`s group in University of Bath, UK. They express many of the hepatocyte 
genes such as Alb, Trf. It should be noted that expression of Alb and Trf in ASH cells is 
lower than the primary hepatocytes. ASH cells are smaller than primary hepatocytes. 
Unlike primary hepatocytes ASH cells are also highly proliferative in tissue culture and 
so far they have been maintained over thirty passages in tissue culture without losing 
their phenotype.  
In this study we decided to use ASH cells to see if small molecules can increase 
the reprogramming efficiency of Ad-PNM for two reasons. Firstly, in Figure 6B by using 
immunostaining technique for insulin protein we showed that nearly 2% of the ASH cells 
become insulin-positive after transduction with Ad-PNM. Stimulation of the expression 
of beta cell genes was also demonstrated in Figure 5D. So any significant increase in the 
number of insulin-positive cells via small molecules can be easily detected in ASH cells. 
Secondly, unlike primary hepatocytes ASH cells are highly proliferative, phenotypically 
stable and form a homogenous population in tissue culture.  
Small molecules which target genes, enzymes and/or signaling proteins have 
recently been commonly used in reprogramming studies. So far many different small 
molecules have been identified and used to alter cell fate and function (Shi, Tae Do et al. 
  125 
2008; Xu, Shi et al. 2008). Maintenance and differentiation of stem cells as well as 
reprogramming of different cell types into each other are some examples in which the 
right small molecules favor the processes. Based on this fact to see if any small molecules 
can increase the reprogramming efficiency of Ad-PNM, we tested some of them together 
with Ad-PNM on ASH cells. We chose thirteen different small molecules which either 
were shown or thought to favor beta cell formation, replication and/or survival in other 
systems. We classified these small molecules into three groups which are: a) chromatin 
modification-related agents such as trichostatin A (TSA), valproic acid (VPA), 
suberoylanilide hydroxamic acid (SAHA), a diazepin-quinazolin-amine derivative (BIX-
01294) and 5-azacytosine (5-AzaC); b) signaling/metabolism agents such as pirinixic 
acid (WY-14643) (an agonist of PPARα and γ), N-[N-(3,5-difluorophenacetyl)-L-alanyl]-
S-phenylglycine t-butyl ester (DAPT) (an inhibitor of Notch), mycophenolic acid (MPA) 
(an inhibitor of IMP dehydrogenase which is used as immunosuppressant), 5'-N-
ethylcarboxamidoadenosine (NECA) (an agonist of adenosine) and nicotinamide; and c) 
retinoic acid (RA) and inhibitors of its synthesis such as disulfiram (tetraethylthiuram 
disulphide) and diethylaminobenzaldehyde (DEAB). 
 
5.1.1 Chromatin Modification-Related Agents 
In mammals, histone deacetylase (HDAC) enzymes are classified into four 
classes; I to IV. Of the HDAC enzyme inhibitors, VPA inhibits only class I HDAC 
enzymes (Gottlicher, Minucci et al. 2001), while TSA and SAHA inhibit both class I and 
II HDAC enzymes (Yoshida, Kijima et al. 1990; Richon, Emiliani et al. 1998; Zhou, 
Marks et al. 2001). 
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Inhibition of histone methyltransferase (HMT) enzymes can impair the 
methylation of histone tails hence altering the gene expression profile. For instance, 
inhibition of G9a HMT enzyme by BIX-01294 was shown to lower H3K9Me2 levels, 
allowing the active transcription of Mage-a2 gene which is otherwise silent in ES cells 
(Kubicek, O'Sullivan et al. 2007). 
DNA base methylation was shown to be removed when the cells are cultured with 
5-AzaC (Taylor and Jones 1982) which is a cytosine analogue and can incorporate into 
DNA. 5-AzaC can form an irreversible covalent bond with DNMT enzyme thus depleting 
activity of the enzyme (Creusot, Acs et al. 1982).  
 
5.1.2. Signaling/Metabolism Agents 
WY-14643 is an agonist of peroxisome proliferator activated receptor-α and -γ 
(PPARα&γ) which can act as transcription factors to increase the expression of many 
genes reviewed in (Mandard, Müller et al. 2004). When rodents are fed for long periods 
of time with WY-14643, it was shown to cause hepatocellular tumors in mice and rats 
(Marsman and Popp 1994; Gonzalez, Peters et al. 1998) via a nongenotoxic mechanism 
(Peters, Cattley et al. 1997). The carcinogenic role of WY-14643 was then shown to be 
due to its hypomethylation effect on genomic DNA as well as on the promoter region of 
C-myc gene which induces cell proliferation (Ge, Wang et al. 2001).  
Nicotinamide is the amide derivative of nicotinic acid. It was shown to have a 
protective effect on beta cell survival as well as function in the animal studies (Knip, 
Douek et al. 2000). In many studies describing protocols for insulin producing cell 
formation from human and mouse ES cells, nicotinamide was used together with other 
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molecules (Soria, Roche et al. 2000; Hori, Rulifson et al. 2002; Ku, Zhang et al. 2004; 
Miyazaki, Yamato et al. 2004; Segev, Fishman et al. 2004; Bai, Meredith et al. 2005; Shi, 
Hou et al. 2005). Effects of nicotinamide alone on the beta cell development from ES 
cells have also been reported (Vaca, Berná et al. 2003; Vaca, Berná et al. 2008).  
Notch signaling can mediate many important cellular functions such as 
differentiation, proliferation and apoptosis in numerous tissue types. Notch proteins are 
cell surface transmembrane-spanning receptors and their interaction with proposed 
ligands initiates a signaling cascade within the cells. Activation of notch signaling upon 
ligand binding is accompanied by proteolytic cleavage of the intracellular domain of 
notch protein (NICD) by the gamma-secretase protease complex (Andersson, Sandberg et 
al. 2011). Upon release, the NICD translocates into the nucleus and associates with DNA-
binding proteins (such as recombination signal binding protein for immunoglobulin 
kappa J region (RBPJ-K) in mammals) to form a transcriptional activator, which activates 
the expression of a set of target genes, including Hes1 (Apelqvist, Li et al. 1999). During 
pancreas development, HES1 represses the expression of Ngn3 which is necessary for the 
formation of endocrine cell precursors (Jensen, Pedersen et al. 2000; Lee, Smith et al. 
2001). Notch signaling was also shown to inhibit acinar and ductal cell development 
(Esni, Ghosh et al. 2004; Fujikura, Hosoda et al. 2006). DAPT was shown to functionally 
inhibit gamma-secretase activity (Dovey, John et al. 2001) hence inhibiting notch 
signaling as well as Hes1 gene activation. Thus, DAPT administration to ASH cells 
together with Ad-PNM may stimulate endogenous Ngn3 expression which can be 
expected to contribute to beta cell neogenesis.  
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MPA, the metabolite of the prodrug mycophenolate mofetil, reduces the guanine 
nucleotide level in the cells by inhibiting GMP synthesis through inosine monophosphate 
dehydrogenase (IMPDH) inhibition (Ransom 1995). Due to its inhibitory role on guanine 
synthesis, it has an antiproliferative effect on cells by preventing DNA replication 
(Allison and Eugui 2000). MPA is also widely used as an immunosuppressive drug as 
well as an antineoplastic agent. In a recent study carried out with zebrafish larvae, MPA 
was shown to induce precocious formation of secondary islets in zebrafish pancreas with 
a significant increase in the number of formed islets when MPA is given during larval 
development (Rovira, Huang et al. 2011). The authors also demonstrated that the 
precocious formation and increased number of beta cells through MPA was due to the 
inhibition of IMPDH with resulting depletion of intracellular guanosine level (Rovira, 
Huang et al. 2011). However, how intracellular guanosine levels are involved in beta cell 
differentiation is still unknown. 
Recently it was also shown that MPA can cause the translocation from nucleolus 
to nucleoplasm of nucleolar proteins such as nucleolin, nucleophosmin and nucleostemin, 
hence changing the nucleolar architecture (Huang, Ji et al. 2008). These proteins are 
preferentially expressed in stem cells and in cancer cells (Tsai and McKay 2002). 
Translocation of nucleolar proteins was shown to be due to the inhibition by MPA of 
rRNA synthesis (Huang, Ji et al. 2008). Related to this, MPA-induced nucleolar stress 
activates p53 through the inhibition of MDM2 by ribosomal proteins L5 and L11 (Sun, 
Dai et al. 2008). 
NECA is a nonspecific agonist of adenosine (Fredholm, IJzerman et al. 2001)  
which can activate adenosine G protein-coupled receptor signaling. Recently, the 
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adenosine signaling has been shown to be important in beta cell regeneration (Andersson, 
Adams et al. 2012). In this paper, the authors showed that some adenosine signaling-
related small molecules particularly NECA can enhance the regeneration of the beta cells 
by contributing to their proliferation in zebrafish larvae in which beta cells had been 
depleted chemically (Andersson, Adams et al. 2012). 
 
5.1.3. Retinoic Acid and Its Modulators 
RA is an active derivative of the endogenous vitamin A which is the only source 
for RA since it can not be synthesized de novo. RA is a lipophilic small molecule and can 
diffuse through the cell membrane. In chordate embryos and adults, RA regulates several 
important cellular functions including cellular proliferation and differentiation (Escriva, 
Holland et al. 2002). The correct balance of RA is also necessary for patterning of the 
anteroposterior axis of the body in vertebrates by controlling the expression of Hox genes 
(Durston, Timmermans et al. 1989; Hogan, Thaller et al. 1992). In many other studies, 
RA was also shown to function in developing the facial region and forebrain (Schneider, 
Hu et al. 2001), eye (Matt, Dupé et al. 2005), inner ear (Romand, Dollé et al. 2006), lung 
(Wang, Dollé et al. 2006), kidney (Batourina, Gim et al. 2001) and pancreas (Rochette-
Egly and Germain 2009). RA functions by binding to nuclear retinoic acid receptor 
(RAR) family members which are RARα, RARβ and RARγ (Ross, McCaffery et al. 
2000). After ligand binding RARs form heterodimers with retinoid-X receptors (RXRs), 
including RXRα, RXRβ and RXRγ. RAR/RXR dimers will then bind to DNA sequences 
which are called RA-response elements (RARE) and activate their target genes. Retinol 
(vitamin A) is first transformed into retinaldehyde which is catalyzed by two enzyme 
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families: cytosolic alcohol dehydrogenases (ADHs) and microsomal retinol 
dehydrogenases (RDHs). Retinaldehyde is then oxidized to RA which is carried out by 
three retinaldehyde dehydrogenase enzymes (RALDH1, RALDH2, RALDH3).  
RA appears to have critical role in development of the pancreas (Martín, Gallego-
Llamas et al. 2005). In this study, the expression of Raldh2 in mesoderm which surrounds 
the budding pancreatic epithelium was shown to be essential for Pdx1 expression in the 
pancreatic dorsal bud, since in its absence the pancreatic dorsal bud did not express Pdx1 
(Martín, Gallego-Llamas et al. 2005). In a recent study, Raldh1 expression was 
demonstrated in pancreatic epithelium of mouse and human at a period coinciding with 
the massive beta cell formation (Öström, Loffler et al. 2008). The authors also showed 
that transgenic mice expressing a dominant negative form of RARα under the control of 
the Pdx1 promoter (Pdx1 is expressed both in pancreatic progenitor cells and beta cells) 
did not develop dorsal or ventral pancreas and died after birth. These results prove the 
necessity of RA signaling in early pancreatic progenitor cells of both dorsal and ventral 
pancreas. In the same study, by using an ex vivo explant system, in which the authors 
cultured the mouse 10.5 dpc dorsal pancreatic buds in serum-free defined medium with or 
without RA, they showed that 25nM RA provides ~2.5 fold increase in the number of 
insulin-positive cells compared to control. However higher concentrations of RA such as 
50nM and 100nM inhibited endocrine cell formation (Öström, Loffler et al. 2008). These 
results demonstrated the stimulatory effect of RA on beta cell neogenesis as well as its 
inhibitory effect on beta cell formation at high concentrations. For that reason in addition 
to RA we also tested the effect of RA inhibitors such as disulfiram and DEAB both of 
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which inhibit the aldehyde dehydrogenase enzyme activity thereby impairing RA 
signaling. 
 
5.2. Experimental Design and Methods 
 
5.2.1. Killing Curve for Small Molecules 
To determine the final concentrations of the small molecules to be used in this 
study, we performed a killing curve assays for each small molecule. For this purpose 105 
mouse hepatocyte-derived small (ASH) cells were plated into each well of a 6-well plate 
and were maintained in low-glucose DMEM medium which was supplied with 10% (v/v) 
FBS and 1x anti-anti solution. One day after we plated the cells, incremental 
concentrations of small molecules were included in the culture. The cells were incubated 
with these small molecules for two days and then the small molecules were removed by 
refreshing the medium. The highest concentration which causes no more cell death than 
of the control cells was chosen as the final concentration for the given small molecule. 
These final concentrations were as follows: 1mM for TSA (diluted in dH2O), 1mM for 
VPA (diluted in dH2O, Sigma), 5μM for SAHA (diluted in DMSO; Sigma), 2μM for 
BIX-01294 (diluted in dH2O; Tocris), 5μM for 5-AzaC (diluted in DMSO), 75μM for 
WY-14643 (diluted in DMSO; Cayman), 10μM for DAPT (diluted in DMSO; Sigma), 
1μM for MPA (diluted in DMSO; Sigma), 10μM for NECA (diluted in DMSO, Tocris), 
5mM for Nicotinamide (diluted in dH2O; Sigma), 100nm for Disulfiram (diluted in 
DMSO; Sigma), 10μM for DEAB (diluted in DMSO; Aldrich), 10μM for RA (diluted in 
DMSO).  
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5.2.2. Administration of Small Molecules and Ad-PNM to the Cells 
After the determination of the final concentrations for each small molecule, the 
same number of ASH cells (105) was plated into each well of 6-well plates (Day 0). The 
cells were allowed to attach to the plates overnight. The next day, each small molecule 
was individually given to the cells in different wells at the final concentrations mentioned 
above (Day 1). After two days incubation with small molecules, the number of the cells 
per well was calculated and 15 MOI Ad-PNM was given without removing the small 
molecules from the medium (Day 3). The next day, both Ad-PNM and the small 
molecules containing medium was removed (Day 4). The cells were maintained in the 
culture for two more days before analysis. 
To see if the small molecules increased the reprogramming efficiency of Ad-
PNM, we decided to count the number of insulin expressing cells as the read out. For this 
purpose, ASH cells were fixed and immunostained for insulin and PDX1 proteins (Day 6) 
as described previously. The number of insulin positive cells as a fraction of viral Pdx1 
bearing cells was calculated by counting the insulin-positive cells from ten randomly 
chosen different areas in each well. Three different wells were counted for each 
experimental group and two different experiments were set up at different times (n=2x3). 
RNA isolation, cDNA synthesis and qRT-PCR experiments for ASH cells, ASH 
cells with DAPT, ASH cells with Ad-PNM, ASH cells with DAPT and Ad-PNM were 
performed as described in Chapters B1 and B3. ELISA for glucose stimulated insulin 
release for ASH cells, ASH cells with DAPT, ASH cells with Ad-PNM, ASH cells with 
DAPT and Ad-PNM were performed as described in Chapter B3. 
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5.3 Results 
Contribution of the different small molecules to the reprogramming efficiency of 
Ad-PNM on ASH cells was shown in the Figure 24. Of the thirteen small molecules used 
in this study, DAPT, NECA and BIX-01294 yielded ~6% (3 fold increase), ~4% (2 fold 
increase) and ~4% (2 fold increase) respectively in the number of insulin-positive cells as 
a fraction of the Ad-PNM bearing cells, where the efficiency of Ad-PNM alone was 2%. 
Unlike DAPT and NECA, other signaling/metabolism agents such as WY-14643 (~3%), 
MPA (~2.5%) and nicotinamide (~2.5%) showed a slight or no increase in the number of 
insulin-positive cells compared to Ad-PNM bearing cells only. Among chromatin 
modifying agents, BIX-01294 (~4%) was the only one making a significant contribution 
to the efficiency of reprogramming into an insulin-positive state through Ad-PNM. The 
rest of them either did not increase the number of insulin-positive cells (VPA and SAHA; 
~2%) or made it worse than Ad-PNM alone (TSA and 5-AzaC; less than ~1%). RA 
(~2.5%) and its negative modulator DEAB (~3%) slightly increased the efficiency of Ad-
PNM whereas another RA modulator disulfiram (~1.5%) made it worse. Moreover 
administration of most responding three small molecules DAPT, NECA and BIX-01294 
at the same time resulted in significant increase (~12%) in number of insulin positive 
cells (Figure 24). 
Gene expression profile comparison between small molecules only, Ad-PNM 
only and small molecules + Ad-PNM including cells with qRT-PCR revealed that when 
used together with Ad-PNM, small molecules (DAPT+NECA+BIX) also increased the 
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expression level of many beta cell genes such as Ins1, Ins2, Pax4, Neurod1, Insm1, Isl1, 
Pcsk1, Pcsk2, Cpe, and Mnx1 (Figure 25).  
Like the increase in expression of beta cell markers, ELISA results showed that 
when used together with Ad-PNM, small molecules (DAPT+NECA+BIX) yielded a 
slight increase in the amount of insulin released into the medium (Figure 26). 
 
5.4. Discussion 
Of thirteen small molecules used in this study, the notch signal blocking agent 
DAPT gave the best result with a three fold increase in the number of insulin-positive 
ASH cells compared to those that were induced with Ad-PNM only. This favorable effect 
of DAPT was probably due to its ability to deplete the notch signal driven-expression of 
Hes1 which otherwise suppresses the pancreatic endocrine cell formation. Through the 
inhibition of gamma-secretase protein complex, DAPT prevents the expression of Hes1 
gene which allows the expression on endocrine cell differentiation factor Ngn3. Our 
results for DAPT is consistent with the studies performed with developing zebrafish 
larvae (Parsons, Pisharath et al. 2009; Rovira, Huang et al. 2011) which demonstrated the 
favorable effect of DAPT on beta cell formation. 
Among chromatin modifying agents tested in our hands, the G9a HMT enzyme 
inhibitor BIX-01294 was the only one which significantly increased the number of 
insulin-positive ASH cells by almost two fold. This was probably due to its effect on 
lowering H3K9Me2 level thereby allowing the active transcription of many genes 
(Kubicek, O'Sullivan et al. 2007). The HDAC enzyme inhibitors such as TSA, VPA and 
SAHA, however, did not increase the number of insulin-positive ASH cells unlike a 
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report in which HDAC enzyme inhibitors were shown to favor Ngn3 expression thereby 
increasing the number of endocrine cells in rat pancreatic bud cultured in vitro 
(Haumaitre, Lenoir et al. 2008). Like most of the histone modification-related small 
molecules used here, the DNA base methylation-related small molecule 5-AzaC, which 
depletes the activity of DNMT enzyme also did not increase the number of insulin-
positive ASH cells.  
The adenosine agonist NECA is another small molecule that resulted in an almost 
two fold increase in the number of insulin-positive ASH cells. It has recently been 
showed that NECA acts through the adenosine receptor A2aa and increases the 
proliferation of specifically beta cells during beta cell regeneration (Andersson, Adams et 
al. 2012). Beside NECA, the authors described three more adenosine signaling-related 
small molecules enhancing the beta cell regeneration during the development of zebrafish 
larvae in which beta cells were depleted previously. Even though we have not tested the 
proliferation ability of NECA-treated insulin-positive ASH cells, it should be noted that 
these cells were already highly proliferative without NECA. Unlike DAPT and NECA, 
other signaling/metabolism agents such as WY-14643, MPA or nicotinamide did not 
make any significant contribution into the formation of insulin-positive cells. Also, 
neither RA nor its negative modulators improved the results. 
When we used these three most effective small molecules (DAPT, BIX-01294 
and NECA) together on the ASH cells, they increased the number of insulin positive cells 
almost 6 fold (~12%). This was an expected result since these three small molecules have 
different mode of actions and targets in the cells. 
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qRT-PCR and ELISA results demonstrated that there is also a slight increase in 
the expression level of many beta cells genes as well as in the amount of the insulin 
released into the medium from the cells when DAPT+NECA+BIX combination used 
together with Ad-PNM. However, increase in the transcript level as well as secreted 
insulin is probably due to increase in the number of the responding cells. We concluded 
that when used together with Ad-PNM, DAPT+NECA+BIX can increase the quantity of 
transformed cells but not the quality of transformation since a) there in no activation of a 
different beta cell marker in DAPT+NECA+BIX & Ad-PNM including samples as 
distinct from Ad-PNM only including cells; and b) there is no increase in the ratio of 
released insulin in low and high glucose environment. 
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Figure 24: Effect of small molecules on cell reprogramming 
Thirteen small molecules were given to ASH cells together with Ad-PNM. Their effect in 
reprogramming efficiency was quantified by comparing the fraction of insulin-positive 
cells after insulin immunostaining. ASH cells were treated with small molecules for 2 
days, then were given Ad-PNM overnight and insulin immunostaining was performed 3 
days after Ad-PNM transduction. Data are means ± S.E. (n =3). 
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Figure 25: Gene expression profile of ASH cells after small molecules and Ad-PNM 
Gene expression profile of ASH cells with no treatment (white bars), with DAPT only 
(light grey bars), with DAPT+NECA+BIX (dark grey bars), Ad-PNM only (black bars), 
with DAPT & Ad-PNM (grey dotted bars) and with DAPT+NECA+BIX & Ad-PNM 
(grey dotted bars) were quantified by qRT-PCR. ASH cells only group was maintained in 
culture for three days. ASH cells with small molecule(s) group were maintained in 
medium supplemented with small molecule(s) for three days. ASH cells with Ad-PNM 
were maintained in culture for three days in which Ad-PNM were given the cells at day 
0. ASH cells with small molecule(s) and Ad-PNM were maintained in medium 
supplemented with small molecule(s) for five days in which Ad-PNM were given the 
cells at day 2. Data are means ± S.E. (n =3). 
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Figure 26: Secreted insulin amount of ASH cells after small molecules and Ad-PNM 
by ELISA 
The amount of insulin in the medium released from ASH cells with no treatment, with 
DAPT only, with DAPT+NECA+BIX, with Ad–PNM only, with DAPT and Ad-PNM, 
with DAPT+NECA+BIX and Ad-PNM was measured by ELISA. Cells were stimulated 
either with low-glucose (white bars) or high-glucose (black bars). Data are means ± S.E. 
(n =3). 
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Chapter 6 Attempts to Sort/Enrich Insulin-Positive Cells after Ad-PNM 
Transduction 
 
6.1. Introduction 
In Chapter B1 we showed the expression of Insulin genes by RT-PCR in eight 
different cell types at varying intensities upon Ad-PNM transduction. Some of these cell 
types activated more beta cell markers than others in addition to Insulin genes. Even 
though the expression of Insulin genes was shown for all the cell types in RT-PCR, 
insulin immunostaining was only detected in five cell types, including primary rat 
hepatocytes (Figure 6A-A`), ASH cells (Figure 6B-B`), AR42J-B13 cells (Figure 6C-C`), 
rat MAPCs (Figure 6D) and CRL-1213 (Figure 6E). On the other hand, for four of these 
cell types (except AR42J-B13 cells) the number of insulin positive cells as a fraction of 
Ad-PNM bearing cells was low; at about 2%. The low concentration of the insulin-
positive cells made it difficult to further analyze these cells to see how close to a genuine 
beta cell phenotype they are. The ideal way to get trustworthy results from these cells was 
to increase the ability to sort and/or enrich the fraction of these insulin-positive cells. To 
accomplish this, we focused on two methods: a) Newport green staining and 
fluorescence-activated cell sorting (FACS), and b) Insulin immunostaining and FACS or 
laser capture microdissection (LCM).  
Newport green is a fluorescent indicator which has a specific affinity for zinc 
(Zn2+) molecule (Gee, Zhou et al. 2002). Intracellular Zn2+ rich cells can be stained and 
visualized with Newport green without any need for fixation and/or permeabilization 
steps hence keeping the cells alive during and after staining. In addition to its other 
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critical functions in biological systems (Beyersmann and Haase 2001), Zn2+ is also 
indispensable for beta cell biology. Insulin proteins are packed and stored in secretory 
vesicles of beta cells as solid hexamers and two Zn2+ ions are necessary for this 
packaging (Chausmer 1998). For that reason, intracellular Zn2+ ions are exceptionally 
abundant in beta cells and can be stained with Newport green staining.  
Newport green was shown to stain insulin expressing, intracellular zinc-rich beta 
cells (Lukowiak, Vandewalle et al. 2001), as well as insulin-positive cells derived from 
human ES cells (Liew, Shah et al. 2008) without fixing and permeabilizing the cells 
thereby keeping them alive. However, in our experiments in which we stained the Ad-
PNM-transduced ASH cells with Newport green dye we did not see any difference 
between insulin-positive and -negative cells. Incubation of experimental and control 
groups with extra Zn2+ resulted in Newport green positivness both for Ad-PNM 
transduced and nontransduced cells. Since there was no true Newport green staining we 
could not sort insulin positive cells through FACS. 
 
6.2. Experimental Design and Methods 
 
6.2.1 Newport Green Staining  
105 ASH cells were plated into each well of a 6-well plate and were maintained in 
low-glucose DMEM which was supplied with 10% (v/v) FBS and 1x anti-anti solution 
(Day 0). The cells were allowed to attach to the plates overnight. The next day, 15 MOI 
Ad-PNM was given to the cells (Day 1). The day after virus administration, Ad-PNM 
containing medium was removed (Day 2). Three days after Ad-PNM transduction (Day 
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5) the cells were stained with 1μM Newport green (Invitrogen). To do this ASH cells 
were washed twice with PBS. The cells were then incubated in 1ml PBS supplied with 
1μM newport green and 1μl pyronic acid (Invitrogen) for 1 h at 37◦C.  
 
6.2.2 FACS and LCM Sorting Following Insulin Immunostaining 
ASH cells were plated into either T-175 tissue culture flasks (for FACS) or PEN-
membrane coated tissue slides (Leica) (for LCM) and were maintained in low-glucose 
DMEM which was supplied with 10% (v/v) FBS and 1x anti-anti solution (Day 0). For 
FACS, a total of 5x107 ASH cells were maintained in ten T-175 tissue culture flasks. For 
LCM 5x105 ASH cells were plated into each slide. The cells were allowed to attach the 
plates and slides overnight. The next day, 15 MOI Ad-PNM was given to the cells (Day 
1). The next day Ad-PNM containing medium was removed (Day 2). Three days after 
Ad-PNM transduction (Day 5) the cells were fixed and stained for insulin protein.  
For FACS, ASH cells were dissociated from tissue culture flasks with TrypLE 
(Gibco) and were collected into RNase-free 1.5ml centrifuge tubes. Formalin fixation, 
permeabilization and all remaining steps for insulin staining were carried out with ASH 
cell suspension in the centrifuge tubes. All the solutions used during staining except 
formalin were supplied with 0.1% (v/v) active diethylpyrocarbonate (DEPC, Sigma) to 
reduce RNA degradation. Guinea pig anti-insulin (1:200 dilution, Sigma) antibody was 
used for primary antibody staining. R-Phycoerythrin conjugated donkey anti-guinea pig 
(1:500 dilution, Jackson ImmunoResearch) antibody was used for secondary antibody 
staining. After the cells were stained for 1 h with each antibody, insulin-positive cells 
were sorted with FACS machine. Approximately 105 insulin-positive ASH cells (1%) 
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were separated from 5x107 ASH cells. Total RNA from the sorted cells was isolated using 
the FFPE RNA isolation kit (Qiagen), which is designed for RNA isolation from formalin 
fixed paraffin embedded tissues, according to the manufacturer's manual.   
DNase treatment and cDNA synthesis were performed as described in Chapter 
B1. One difference was that RNA samples were incubated at 70◦C for 15 min before 
cDNA synthesis to reduce the formaldehyde induced cross linking. Random primers 
(Invitrogen) instead of oligo(dT)20 were also used during cDNA synthesis. The gene 
expression pattern between insulin-positive and negative ASH cells was then compared 
by performing qRT–PCR as described in Chapter B3. The primer pairs used in this qRT–
PCR were designed for small amplicons such as less than 100bp and were listed in Table 
5. 
 
6.3. Results 
LCM sorting of formalin-fixed, insulin-immunostained ASH cells posed another 
challenge as we could not isolate enough cells for applications such as qRT-PCR. The 
problems we encountered during LCM were as follows: a) The laser which dissects the 
cells out is not fine enough. In order not to burn the insulin-positive cell of interest with 
the laser a wide circle should be drawn which then burns the neighboring insulin-positive 
cells. b) The slide and the cells on it start to dry during laser dissection which causes a 
background signal which makes it difficult to identify the true insulin-positive cells. c) 
Laser dissection of a single cell takes at least 10 sec and considering at least 105 cells is 
necessary for RNA isolation from formalin fixed cells, it takes roughly 250 h to isolate 
enough number of cells with LCM. 
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FACS of formalin-fixed, insulin-immunostained ASH cells gave better results 
than LCM. Approximately 105 insulin-positive ASH cells (1%) were sorted from 5x107 
ASH cells with FACS. The whole procedure from fixation/staining to sorting took 7-8 h 
during which cells were preserved in active DEPC-containing solutions. 4μg total RNA 
was isolated from the sorted cells. This amount was lower compared to the total RNA 
yield from control cells but high enough to prepare cDNA for qRT-PCR. The gene 
expression difference between Ad-PNM-transduced, insulin-immunostained, FACS-
sorted ASH cells and no virus-treated, secondary antibody-immunostained, FACS-sorted 
ASH cells was shown in Figure 27.  
 
6.4. Discussion 
The fraction of insulin-positive cells for Ad-PNM-transduced AR42J-B13 cells 
was approximately 70%. This ratio was high enough to get accurate and reliable results 
from a heterogenous cell population in which Ad-PNM bearing insulin-positive cells, Ad-
PNM bearing insulin-negative cells, and cells with no Ad-PNM are present. However the 
low fraction of insulin-positive cells in other cell types such as ASH (~2%) after Ad-
PNM transduction made it difficult to further analyze the insulin-positive cells. For that 
reason, in this section we were motivated to find out a way to sort/enrich the fraction of 
insulin-positive cells from remaining unresponsive cells. 
Unlike cells which have a unique cell surface protein, until now there are no 
known cell surface proteins for beta cells. A2B5 antibody, which primarily binds to 
gangliosides of various neural tissue cells, was shown to bind to plasma membrane of 
islet cells (Eisenbarth, Shimizu et al. 1982). However, none of the insulin-positive cell 
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types we obtained after Ad-PNM transduction were stained with this antibody (results are 
not shown).  
The impossibility of a live beta cell sorting via FACS due to the absence of a 
unique cell surface protein in beta cells was overcome by the use of Newport green 
staining which stains the intracellular Zn2+ ions highly abundant in beta cells (Lukowiak, 
Vandewalle et al. 2001; Liew, Shah et al. 2008). However, like A2B5, Newport green 
staining did not label our insulin-positive cells. As proven in many of the experiments 
performed in this dissertation, even though the effects of Ad-PNM are dramatic on the 
cell types we used, the reprogramming event is not complete in any of them and eventual 
insulin-positive cells are not true beta cells. Because of this incomplete reprogramming, 
our insulin positive cells may not have developed proper targets for A2B5 antibody hence 
remaining irresponsive. For the same reason, intracellular insulin content may not have 
packed into cellular granules properly thereby eliminating the necessity of high 
intracellular Zn2+ content. Alternatively the failure of Newport green staining may simply 
have been due to the low amount of the insulin produced by our cells. 
After these unsuccessful attempts to sort insulin-positive cells alive, we decided to 
sort them via insulin immunostaining. Since we have to fix and permeabilize the cells for 
immunostaining of cytoplasmic insulin protein, the cells will not be alive after sorting 
which highly limits the downstream applications (i.e. glucose stimulated insulin response, 
cell transplantation) for these cells. However, the gene expression profile of these 
enriched insulin-positive cells can be quantified by qRT-PCR if a sufficiently high 
quality and quantity of total RNA can be isolated. Isolation of total RNA from formalin 
fixed cells/tissues is challenging because a) RNA bases show covalent modifications 
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(Evers, Fowler et al. 2011), and b) RNA strands are fragmented into smaller pieces 
(Hewitt, Lewis et al. 2008) after formalin fixation. These effects of formalin on RNA 
fragments make RNA isolation and cDNA synthesis from isolated RNA difficult. To 
overcome these problems we first reduced the duration of cell fixation (15 min) and 
primary/secondary antibody staining (30 min for each). The solutions used during 
staining and sorting were supplemented with active DEPC to prevent further strand 
fragmentation. The LCM technique was not practical to collect enough cells because of 
the reasons mentioned above. However, we succeeded to sort 105 insulin-positive cells 
out of more than 5x107 cells in a reasonable time (4-5 h) with FACS. Total RNA from 
these cells was isolated using a FFPE RNA isolation kit (Qiagen) which was designed for 
RNA isolation from formalin treated samples. Briefly kit uses proteinase K enzyme to 
degrade the proteins cross-linked to RNA to make RNA isolation more efficient. 
Moreover during the isolation cell extracts are also heated up to 80◦C to reverse the 
modifications on the RNA bases. Still RNA is fragmented into small pieces and we used 
random primers instead of oligo(dT)20 when making cDNAs from these fragmented 
RNAs. We also designed primers to be used in qRT-PCR for small amplicons such as 
less than 100 bp. All these small modifications performed during experiments improved 
the qRT-PCR results to a large extent.  
All in all, even though it does not allow us to perform more downstream 
applications after the sorting, FACS isolation of the formalin fixed, insulin-
immunostained ASH cells gave us an opportunity to quantify the gene expression profile 
of these enriched insulin positive cells in a more accurate and reliable way than those that 
not sorted, 2% insulin-positive cell including, heterogenous ASH cell population.  
  150 
Figure 27: Gene expression profile of insulin immunostained FACS sorted ASH cells 
Gene expression profiles of FACS sorted insulin-positive ASH cells after Ad-PNM 
transduction were quantified by qRT-PCR. ASH cells were transduced with Ad-PNM. 
Three days after transduction, the cells were fixed with formalin and immunostained for 
insulin protein. Insulin-positive ASH cells were sorted using FACS. qRT-PCR was 
performed for the insulin-positive (grey bars) and -negative cells (white bars) for some 
important beta cell markers. Data are means ± S.E. (n =2). 
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Table 5: Mouse primers used for small amplicons
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Mouse Primers used for small amplicons 
Primer 
name Forward Sequence 5`-3` Reverse Sequence 5`-3` 
Ins1  TGCTCCCTCTACCAGCTG CATTGCAGAGGGGTGGG 
Ins2 GGCTTCTTCTACACACCCATG CACCCAGCTCCAGTTGTG 
Pdx1  GATGAAATCCACCAAAGCTCAC TCTTGTTTTCCTCGGGTTCC 
Pdx1 UTR CACAGCCCTCCAGCATC CCGCTCACCCTCAGACT 
Slc2a2 AATTACCGACAGCCCATCC TCCCATTGATTCCTGAGAACTG 
Kcnj11 CGGAGAGGGCACCAATG AGGAAGGCAGATGAAAAGGAG 
Abcc8 CATGGAGACCAGACTCAGATTG ACTGATTCGCTGACGCTG 
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Chapter 7 Conclusion and Future Directions 
 
The loss of beta cells at the onset of type 1 and at the late stage of type 2 diabetes 
necessitates a new source of insulin hormone for proper control of the glucose 
metabolism. Current therapies such as insulin replacement (i.e. insulin shots, insulin 
pumps) and islets and/or whole pancreas transplantation can treat the disease to some 
extent but not cure it. The production of insulin-producing, glucose-responsive beta-like 
cells from patients` own cells can solve many of the problems encountered in the present 
treatments. Due to this possibility, many studies related to beta-like cell reprogramming 
have been performed recently. In one of these studies Zhou et al. showed the ability of 
the combination of Pdx1, Ngn3 and MafA genes to reprogram the mouse exocrine acinar 
cells into insulin producing beta-like cells.  
In this dissertation we studied the effect of the same transcription factors used by 
Zhou et al., but cloned all three genes into single adenoviral construct. First, we 
investigated the reprogramming competency to Pdx1, Ngn3 and MafA of different cell 
types at different developmental stages from mouse and rat. Second, we looked at the 
effect of these three genes on a pancreatic rat exocrine cell line AR42J-B13 to see if this 
gene combination provides a true beta cell reprogramming event. Next, we investigated 
the effect of some small molecules to see if they increased the reprogramming efficiency 
of this gene combination. Finally we tried to sort the small fraction of insulin-positive 
cells formed after Pdx1, Ngn3, MafA transduction to enrich the insulin-positive cell 
population hence getting more accurate data from them. 
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Transduction of different cell types with Ad-PNM showed that the Pdx1, Ngn3 
and MafA gene combination is enough to stimulate the expression of Insulin genes with 
varying intensities depending on cell type. Rat cell lines responded to Ad-PNM in a 
better way than mouse cell lines by activating more beta cell genes. The number of 
responding cells to Ad-PNM was also higher for the rat cell lines than the mouse cell 
lines. Moreover progenitor-like cells as well as the cells developmentally related to beta 
cells are prone to be reprogrammed into beta-like state. Supporting this final statement, 
embryonic mouse heptoblasts from Pdx1-GFP transgenic mice gave the most promising 
result by activating the endogenous Pdx1 as well as many other important beta cell genes 
upon transduction with Ad-PNM. 
Further characterization of the effect of Ad-PNM on the most resposive cell type 
AR42J-B13 cells showed that after Ad-PNM the cells became post-mitotic, began to 
express Insulin genes together with many other beta cell genes, produced mature insulin 
hormone, changed the epigenetic state of their chromatin, and rescued diabetic mice if 
transplanted into the kidney capture. However, some important beta cell genes were not 
activated thereby making these cells unresponsive to glucose which is an indispensable 
beta cell quality. It is obvious that even though the changes are dramatic, the combination 
of Pdx1, Ngn3 and MafA did not provide a true beta cell reprogramming in vitro at least 
for this cell system.  
Among some of the small molecules which had been reported to favor beta cell 
formation, regeneration and/or survival, three of them including DAPT, BIX-01294 and 
NECA increased the effect of Ad-PNM on mouse hepatocyte-derived small cells. 
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Moreover when all three were used together they showed a better efficiency. Even though 
there was a significant increase in the number of insulin positive cells, the fraction of the 
Ad-PNM-responding cells was still low after the small molecules. For that reason the 
effect of small molecules on reprogramming efficiency of Ad-PNM was compared by 
counting the fraction of insulin-positive cells out of Ad-PNM-bearing cells between 
control and experimental cell groups instead of performing qRT-PCR. 
Of the attempts that we performed to increase the low fraction of insulin-positive 
cells via different sorting techniques to get more accurate and reliable results from Ad-
PNM responding cells, only fluorescence-activated cell sorting of insulin-immunostained 
cells worked. Even though these cells were enriched through the FACS, because the cells 
were nonviable not alive we could not perform any downstream application that 
necessitate living cells. This system allows us to do qRT-PCR only.  
To form insulin-expressing beta–like cells from other cell types, the combination 
of Pdx1, Ngn3 and MafA is one of the best candidates because of the roles of these factors 
during beta cell development. Dramatic effects of this combination on the cells tested 
also support this idea. Incomplete reprogramming of the tested cell systems, however, is 
still an important issue which needs to be solved in the future studies. We verified that 
three small molecules reported previously by others increase the number of insulin-
positive cells after Ad-PNM. For that reason simultaneous administration of a true 
combination of small molecules and transcription factors can provide genuine beta cell 
formation in vitro. 
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Our preliminary results (not shown here) demonstrated that low and high levels of 
Ad-PNM prevent the insulin-positive cell formation. For our experiments 25 MOI Ad-
PNM was the optimum dose and gave the highest number of insulin-positive cells. This 
result underscores the importance of amount of the transcription factors for 
reprogramming events. For that reason instead of simultaneous changes in the amount of 
Pdx1, Ngn3 and MafA genes, their different combinations should be tested in future 
experiments.  
The main purpose behind these experiments was to identify an alternative beta 
cell source for diabetic patients. For this purpose, all these experiments should also be 
upgraded to human cell studies to see if they can be reprogrammed into true beta cells.  
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